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INT.ROW CTI ON 
Aminoglycoside antibiotics are irn}:x:>rtant in the treabnent of 
serious to life-threatening bacterial infections. 'Ihese antibiotics 
are used extensively as evidenced. by the approximately 3 million doses 
given annually in the United states alone. HDW'ever, the use of 
aminog1ycoside antibiotics is often hanjpered by associated toxicities. 
One of the most common toxicities encountered with these antibiotics 
affects the kidneys (nephrotoxicity). Although aminoglycoside 
nephrotoxicity is usually reversible and mild in severity, it can 
result in some degree of morbidity and lengthen hospital stay. If gone 
undetected, however, aminoglycoside nephrotoxicity can progress to 
irreversible renal (kidney) failure and cond.emn a patient to dialysis 
(Cooper & Bennett, 1987). 
Considerable research has been directed at dete:rmining the 
interrelationships between aminoglycoside antibiotics and 
nephrotoxicity. Gentamicin and tobrarnycin specifically, have drawn a 
great deal of attention, particularly after early animal data ind.icated 
that tobrarnycin might be asscx:::iated with less nephrotoxicity than 
gentamicin (Kahl.meter & Dahlager, 1982). Comparative clinical trials 
have produced. discrepant results as to whether gentamicin is associated 
with nephrotoxicity more often than tobrarnycin (Burkle, 1986). Results 
from the same investigators have even been discrepant (Smith, Lipsey, 
Iaskin, Hellmann, Mellitis, IDngstreth, & Liebnan, 1980; Moore, Smith, 
Lipsey, Mellits, & Liebnan, 1984). 
Several atterrpts have been made to discern from the errpirical 
research whether there is a difference in the incidence of 
1 
nephrotoxicity between gentamicin and tobramycin (Burkle 1986; Cone, 
1982; Darr & Elenbaas, 1981; Hubler, 1984; Kahlmeter & Il9hlager, 1982; 
Meyer, 1986; Smith & Ll.etJnan, 1982). However, the conclusions 
presented in these reviews have been as discrepant as the ind.ependent 
empirical (i.e. primary) f :i.n:::lings. 
2 
'Ihe question of gentamicin and tobramycin ~tive 
nephrotoxicity is important because if tobramycin is associated with 
less nephrotoxicity than gentamicin, morbidity related to gentamicin 
nephrotoxicity could be reduced by preferentially using tobramycin. 
HDW'ever, since gentamicin is significantly less expensive to use than 
tobramycin, if there is no difference in nephrotoxicity between them, 
then by using gentamicin preferentially, financial resources that would 
have been consumeCl by tobramycin use could be reallocated for other 
purposes. 
Given that which is reported. above, it is apparent that the 
previously published reviews of the empirical research comparing 
gentamicin and tobramycin nephrotoxicity yielded inconsistent results. 
It is important to note that meta-analytical techniques were never 
systenatically applied to the existing database. In the study 
discussed belCM, meta-analytical techniques were used in an attempt to 
provide a better understanding of the ~tive nephrotoxicity of 
gentamicin and tobramycin than achieved by the previously published 
narrative reviews. 
Meta-analysis represents a group of methodologies that are used 
to systenatically and quantitatively combine results of ind.ividual 
empirical research efforts to derive conclusions that may not be 
3 
achievable otherwise. Meta-analyses are distinguished from narrative 
reviews by their quantitative nature. 'Ihe proce:lure has been 
criticized because of the heterogeneity that may exist among the 
results and methcxls that are combined. Al though there are methcxls to 
control for the possible heterogeneity across studies, meta-analytic 
synthesis of research findings will never take the place of a 
well-done, definitive study. Meta-analytic procedures are perhaps best 
reserved for situations where definitive studies are not logistically 
possible, or as an exploratory activity to determine whether such a 
study should be undertaken (Mintz, 1983). 
Considering the importance of the comparative nephrotoxicity of 
gentamicin and tobramycin, and the discrepancy that presently exists in 
both the primary and secondary literature, a meta-analysis might 
provide a better overall picture. 'Ihus, a meta-analysis of the 
comparative nephrotoxicity of gentamicin and tobramycin was undertaken 
to primarily dete:nnine in a quantitative fashion whether such a 
difference exists, and if so, to "What de;:Jree. 
A parametric meta-analytic procedure (standardized mean 
differences) was used to detect and quantify any differences in the 
comparative nephrotoxicity of gentamicin and tobramycin. HO'Wever, not 
all comparative studies of gentamicin and tobramycin nephrotoxicity 
provided enough infonnation to apply the parametric procedures. 
Therefore, a mcxtified vote-counting method was used to analyze those 
studies that could not be analyzed by the parametric procedures. Thus, 
a secondary purpose of this research project was to compare these two 
meta-analytical techniques. 
REVIEW OF REIATED LITERA'IURE 
COmparative Nephrotoxicity of Gentamicin and Tobramycin 
Aminoglycoside antibiotics. Aminog'lycoside antibiotics are a 
group of antibiotics that share similar chemical structures and 
properties. Many of the aminoglycoside antibiotics are commonly used 
in the trea'bnent of serious to life-threatening bacterial infections. 
In same cases they represent the most effective or the only effective 
antibiotics available (Pancoast, 1988). 
The first aminoglycoside antibiotic made available for general 
clinical use in the United States was streptomycin in 1944. 'Ihe next 
aminoglycoside antibiotic to be approved for use was kanamycin in 
1957, followed by gentamicin in 1969, tobramycin in 1975, a:mikacin in 
1976, and netilmicin in 1983. 'Ihe aminoglycosides antibiotics have 
seen extensive use with approximately three million doses administered 
annually in the United states (Pancoast, 1988). 
'Ihe use of aminoglycoside antibiotics, hOVJever, is hampered by 
their asscx;iated toxicity. The most common toxicities encountered with 
the use of aminoglycoside antibiotics are ototoxicity and 
nephrotoxicity. ototoxicity refers to toxicity affecting auditory 
function and nephrotoxicity refers to toxicity affecting kidney 
function (Pancoast, 1988). Nephrotoxicity, spec:ifically, has been the 
subject of significant research and debate. Part of the research and 
debate has concerned the relative nephrotoxicity of one aminoglycoside 
to another, particularly gentamicin and tobramycin (Kahlmeter & 
Dahlager, 1984). 
Aminoglycoside nephrotoxicity. Nephrotoxici ty O<'.DlrS in 
4 
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approximately 10-20% of aminc.qlycoside courses of therapy. 
Aminoglycoside antibiotics are taken up into renal tubular cells; 
however, the cellular mechanism of toxicity is not known. The 
clinical presentation of aminoglycoside nephrotoxicity is usually an 
asy:rrptoroatic accumulation in the serum of measurable metabolic prcxlucts 
that are nonnally excreted by the kidneys (Cooper & Bennett, 1987). 
For exanple, creatinine, which is a metabolic prcxluct of muscle, is 
prcxluc.ed at a relatively constant rate and is excreted by the kidney. 
Therefore, as renal function decreases (as occurs secondary to 
nephrotoxicity), excretion of creatinine decreases correspondingly and 
accumulates in the serum (Ravel, 1978) • Other m:mifestations of 
nephrotoxicity can include detection of various enzymes or proteins in 
the urine (Schentag, 1983). 
Aminoglycoside nephrotoxicity typically occurs within seven to 10 
days after initiation of therapy and is usually reversible with 
discontinuation. Aminoglycoside nephrotoxicity that goes undetected 
can progress to severe degrees ultima.tely requiring dialysis. Risk 
factors that have 1:::leen associated with aminoglycoside nephrotoxicity 
include age, aminoglycoside dose, duration of therapy, recent 
aminoglycoside exposure, preexisting renal dysfunction, concurrent 
administration of other nephrotoxins, p::>tassitnn depletion, and 
intravascular vol1.m1e depletion (Cooper & Bennett, 1987). The degree 
to which specific aminoglycoside antibiotics contribute to the risk of 
nephrotoxicity has 1:::leen the subject of considerable debate. 
Gentamicin and tobramycin nephrotoxicity. Farly anima.l data 
suggesting that tobramycin might be less nephrotoxic than gentamicin 
6 
resulted. in subsequent clinical trials (COoper & Bennett, 1987). 'Ihe 
in'portance of detenn.ining the comparative nephrotoxicity of gentamicin 
arrl tobrarr(Ycin encompasses both clinical arrl economic considerations. 
From a purely clinical perspective, even the slightest suggestion that 
tobrarr(Ycin is less nephrotoxic than gentamicin would lead many 
clinicians to use tobrarr(Ycin to :minimize any urrlue morbidity related to 
gentamicin. However, economic considerations cloud the decision 
because tobrarr(Ycin is several times more expensive to use than 
gentamicin. If there is no difference in the degree of nephrotoxicity 
associated. with gentamicin arrl tobrarr(Ycin, then use of gentamicin 
would pennit reallocation of the financial resources necessai:y for 
tobrarr(Ycin to other uses. 
Published comparative studies of gentamicin arrl tobrarr(Ycin 
nephrotoxicity have produced equivocal results; some studies showing 
tobrarr(Ycin to be less nephrotoxic than gentamicin "While others showed 
no difference. Many authors (Burkle, 1986; Cone, 1982; Darr & 
Elenbaas, 1981; Hubler, 1984; Kahl.meter & Dahlager, 1982; Meyer, 1986; 
Smith & Lietman, 1982) have attenpted. to evaluate the errpiric research. 
'Ihese evaluations were either narrative reports with subjective 
conclusions or analyses of pooled data; none of "Which used recognized 
meta-analytical techniques. Like the errpiric research they reviewed, 
these evaluations produced equivocal conclusions. 
Burkle (1986), Darr arrl Elenbaas (1981), Hubler (1984), Meyer 
(1986), arrl Smith arrl Lietman (1982) each reported the results of 
published canparisons of gentam.icin arrl tobrarr(Ycin nephrotoxicity, 
cited methodological arrl clinical considerations, arrl rendered 
subjective conclusions. Burkle evaluated 12 c:arrparative trials and. 
concluded "that these 12 clinical trials failed to demonstrate any 
difference in nephrotoxicity between these agents" (p. 516). Hubler 
reached a similar conclusion after evaluating 15 c:arrparative trials, 
stating " the results of controlled studies in humans suggest that 
there are no marked clinical differences in the nephrotoxicity of 
gentamicin and. tobraroycin" (p. 3), as did Meyer in stating that "it is 
still too risky to conclude definitely that one agent is significantly 
less nephrotoxic that another and. that controversy still abounds" (p. 
126). In contrast, after evaluating approximately the same published 
database, Darr and. Elenbaas concluded "that tobraroycin has less 
nephrotoxic potential than does gentamicin" (p. 325) and. Smith and. 
Liet::man concluded "tobraroycin causes nephrotoxicity less frequently 
than does gentamicin" (p. 507) • 
Cone (1982) and. Kahl.meter and Dahlager (1982) attempted 
quantitative analyses of the c:arrparative studies of gentamicin and. 
tobraroycin nephrotoxicity. Cone pcoled the results as reported in 
selected c:arrparative studies and. conducted pairwise corrpa.risons 
(chi-square) to test for statistical significance. '!he difference 
between gentamicin and. tobraroycin nephrotoxicity did not reach 
statistical significance. Similarly, Kahl.meter and. Dahlager pcoled the 
results as reported from selected comparative studies of gentamicin and 
tobraroycin nephrotoxicity. However, the pcoled proportions of 
gentamicin and. tobraroycin nephrotoxicity (14% versus 12.9%) were not 
subjected to hypothesis testing. 
In sununa.ry, despite several attempts to determine the comparative 
7 
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nephrotoxicity of gentamicin and tabramycin by summarizing published 
results, the question of comparable nephrotoxicity still rema.ins. 
Applying meta-analytical techniques to this database could provide more 
meaningful inf onnation than the previously published reviews to help 
solve this important question. 
Meta-Analysis 
Definition and characterization. Definitions and 
characterizations of "meta-analysis" va:r:y because meta-analysis as a 
research methodology is relatively new and is still evolving (Mintz, 
1983). The beginning of meta-analysis as a distinct methodological 
entity has been traced to Glass in 1976 (Mintz, 1983; Thacker, 1988); 
however, research techniques associated with meta-analysis had been 
employed prior to 1976 (Glass, Mc::Gaw, & Smith, 1981; Ieviton & Cook, 
1981; Sacks, Berrier, Rei'bnan, Ancona-Berk, & Chalmers, 1987). 
Glass (1976) originally defined meta-analysis as "the statistical 
analysis of a large collection of results from individual studies for 
the purpose of integrating the findings" (p. 3). later, Glass, McGaw 
and Smith (1981} defined meta-analysis as "the analysis of analyses 
(i.e., the statistical analysis of the findings of many individual 
analyses) 11 (p. 12). other definitions of meta-analysis are similar. 
Mintz (1983) defined meta-analysis as "a quantitative methodology for 
integrating empirical research literature" (p. 71). Meta-analysis is 
defined by Thacker (1988) as "an attempt to irrprove traditional methods 
of narrative review by systematically aggregating infonnation and 
quantifying its lirpact" (p. 1658), and by L'Abbe, Detsky and O'Rourke 
(1987) as "the process of combining study results that can be used to 
draw conclusions about therapeutic effectiveness or plan new studies" 
(p. 224). 'Ihus, most authors define meta-analysis as a method or as 
methods to combine empirical (i.e., primacy) research for the purpose 
of deriving or inproving generalizations. 
Glass et al. (1981) have characterized meta-analysis as a method 
by which quantitative analyses of empirical research are conducted by 
adopting an "attitude" of data analysis (i.e., using measurement and 
statistical analysis techniques). It can be considered as a methcrl of 
summarizing an accumulated knowledge and highlighting :i.nportant 
aspects ('Ihacker, 1988). Meta-analysis also addresses research 
questions that rema.in unresolved ~ (a) empirical data are in 
I 
disagreement as to the direction or ma.gnitude of an effect, (b) sample 
sizes used in the primacy research were too small to detect an effect, 
9 
or (c) the large trials necessary are not logistically feasible (L'Abbe 
et al. 1987). In contrast to traditional narrative reviews in which 
typically there are no rules by vmich the reviewer assesses the 
relevant primacy research, meta-analysis requires systematic approaches 
to aggregating empirical infonration and quantifying its effect to 
produce more ·ruid generalizations (Fiske, 1983; 'Ihacker, 1988) • 
Corrrrnon to the definitions and characterizations of meta-analysis 
is the "quantitative" nature of the methods used to review empirical 
research, particularly relative to the traditional "narrative" 
methods. 'Ihe degree to which meta-analysis "quantifies" empiric 
research is variable and often limited. Mintz (1983) conceptualized 
the review process on a continuum based on the degree to which 
quantitative methods are used as follCMS: 
As the review prcx::ess progresses from the descriptive narrative 
summary to the abstract heights of the multiple regression 
analysis, a series of steps is taken by the reviewer. Each step 
involves increased quantification and abstraction. (p. 71) 
Thus, on one end of the continmnn are narrative reviews in which 
quantitative integration of empiric research is absent and 
subjectivity reigns. The next step aloncJ the continmnn firds 
10 
narrative reviews that include tabular or graphical presentations of 
the ernpiric research substrate that invite mmnnarization but do not 
integrate individual findings or synthesize new info:nna.tion. The next 
step crosses into meta-analytic methcxiology 'Wherein codincJ schemes are 
userl to facilitate descriptive mmnnaries of the ernpiric research. The 
complexity of methcrlologies continue to increase al011CJ the continmnn to 
ultimately "the introduction ot:)pferential statistical hypothesis 
1 
testincJ" (p. 72) • 
Although quantitative aspects are ernphasizerl 'When definincJ or 
characterizincJ meta-analysis, there are necessary qualitative aspects 
as well. For example, qualitative judgments in a particular 
meta-analysis could include the population of studies considererl 
relevant, the scope of the ernpiric research substrate to analyze, and 
the methcxiological approaches to ernploy (Ieviton & Cook, 1981). Thus, 
11just as quantitative research presupposes qualitative judgments, so 
qualitative research is inpossible without quantitative estimates" (p. 
232). 
Nomenclature. ''Meta-analysis" was the tenn used by Glass in 1976 
to denote methcxis by which ernpirical research is integraterl to 
emphasize or synthesize info:nna.tion from large bcx:lies of data. 
However, like the methcxiologies of meta-analysis, the nomenclature 
11 
remains unsettled (Light, 1987). 
Meta-analysis is a tenn used frequently in both the social (Glass 
et al., 1981) and medical sciences (L'Abl:::le et al., 1987). "Research 
integration" and "research synthesis" are also tenns that have been 
used with same re;JU]_arity, "While other authors prefer the tenn 
"ovezview'' (Light, 1987) • Presently none of these tenns refer to 
specific types of methods to integrate empiric research, and are 
therefore used interchangeably. Tenns used exclusively in the 
physical sciences for meta-analysis are "critical review" and "critical 
evaluation" (Hedges, 1987). 
Need for meta-anal vs is. One model for scientific research 
specifies two carrq;xments. 'Ihe first COIIpOnent is empiric research from 
'Which primary data are derived. 'Ihe second COIIpOnent is integration 
and interpretation of the results of empiric research. Meta-analysis 
sezves as one methodological approach to this second component of 
scientific research of integration and interpretation (Fiske, 1983). 
The need for the second COIIpOnent of scientific research in 
clinical medicine relates to the variability in results that occur 
despite the use of oontrolled methods in empiric research such as the 
randomized controlled trial. Horwitz (1987) enunciated the problem as 
follavs: 
Clinical medicine is awash in controversy. At every level of 
clinical practice today, from prevention of the chronic diseases of 
aging such as cancer, to the treatment of acute disorders such as 
myocardial infarction, the evaluation and application of medical 
therapies is assailed by disagreement and uncertainty. In 
contemplating the health hazards of such diverse entities as 
tampons (and the alleged risk of toxic shock syndrome) or aspirin 
(and the alleged risk of Reye's Syndrome), the methodologic 
strategies and details of the research are frequently challenged 
and criticized, creating controversy and dissention in the 
12 
scientific literature and. the public press. (p. 91) 
Reasons for the state of the medical literature as Horowitz 
describes it have been attributed to specific methodolcx3"ical errors or 
problems inherent in the research paradigm itself. Specific 
rnethodolog-ical errors can include experimental designs that result in 
bias or statistical shortcomings such as insufficient sanple sizes or 
eniployment of inappropriate analytical techniques. Inherent problems 
in research paradigms often relate not to compliance with the 
componentry of the paradigm, but with the variable interpretations of 
their use and. applications (Horowitz, 1983). 
'!he narrative review has been the predominant method by which 
enipiric research has been assessed in the clinical medicine literature. 
Prior to the acceptance and. application of controlled. methods of 
experimentation in clinical research, the fo:rm of the published. medical 
literature was primarily reports of random observations. '!bus, there 
was little primary research that could be integrated; and. therefore, 
the narrative review served. to describe the state of the art (fye, 
1987). 
As controlled. methods of experimentation in clinical research 
became widely applied., mostly in the fo:rm of randomized controlled 
trials, narrative reviews became less reliable as a means to summarize 
the enipiric data. '!be burgeoning size of the medical literature, as a 
result of specialization and. the pressures to publish, also add to the 
inadequacy of narrative reviews to accurately summarize primary data 
(fye, 1987) • From Janua:ry 1, 1984 to August 1, 1986 alone, 
approximately 6,000 randomized. clinical trials were indexed. inMEDLilIB 
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(Chalmers, Levin, Sacks, Reibn.an, Berrier, & Nagalingam, 1987b). 'Ihus, 
as the conplexity and amount of the e.npiric research continue to 
increase, the chance for misinterpretation and bias will increase 
accordingly (Einarson, McGhan, Boobn.an, & Sabers, 1985; Strube & 
Harbnann, 1983; '!hacker, 1987). 
It could be argued that what is needed are not methods to 
integrate e.npirical research, but e.npiric research that is conducted to 
definitely answer the research questions at hand. Hovvever, logistical 
considerations often preclude design of the definitive e.npiric research 
effort, particularly those that will likely only demonstrate small to 
mcx:ierate magnitudes in effect that necessarily require large sample 
populations difficult to assemble (Collins, Gray, Godwin, & Peto, 
1987). '!he inherent nature of the ra:rrlomized clinical trial paradigm 
also often produces divergent results from seemingly identical methods 
(Horovvitz, 1987). 'Ihus, as Fiske (1983) noted: 
In the long-range perspective, no one study makes much difference 
(except the rare one that falls more in the context of discovery by 
uncovering something previously undemonstrated). Granted that the 
single study may stimulate or irritate in a healthy fashion, only 
the distillations from the entire body of research in an area have 
lasting effects. (p. 65) 
'!he meta-analysis of Yusef, Collins, Peto, FLU:berg, Stampfer, 
Goldhaber, and Hennekens (1985) assessing the effect of intravenous 
fibrinolytic therapy for acute myocardial infarction is an illustrative 
example. Prior to their meta-analysis, the place of fibrinolytic 
therapy for acute myocardial infarction had been uncertain despite the 
publication of over 20 clinical trials over a period of 25 years. Of 
the 24 ra:rrlomized clinical trials of intravenous f ibrinolytic agents 
for acute myocardial infarction included in the meta-analysis, only 
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five suggeste::i any benefit from this therapeutic intervention in tenn.s 
of mortality. However, Yusef et al. derived an overall reduction of 
mortality of approx.irnately 22% using the odds ratio of mortality in the 
fibrinolytic groups to mortality in the control groups. 'Ihe overall 
odds ratio was derived by weighting irxtivid:ual study odds ratios 
inversely by variance. It thus appeared that intravenous fibrinolytic 
therapy for acute myocardial infarction could affect a mortality 
benefit, but that the magnitude of effect might be rocxierate thereby 
necessitating large sample sizes for reliable detection. As a result 
of this meta-analysis, two large, multi-center, rand.ornized, 
placebo-controlled trials were und.ertaken to confinn these findings. 
P>Oth the Grupp:> Italiano Per lo Studio Della Streptochinasi 
Nell'Infarto Miocardico (GISSI) (1985) trial and. the ISIS-2 (Second 
International Study of Infarct survival) Collaborative Group (1988) 
trial that enrolled 11,806 and. 17,189 patients, respectively, 
demonstrated a reduction in mortality associated with the use of 
intravenous fibrinolytic therapy (streptokinase) for acute myocardial 
infarction of a similar magnitude as the Yusef et al. meta-analysis. 
In surmnacy, it is rare that an irxtivid:ual empirical research 
effort can provide definitive and reproducible results. 'Iherefore, 
meta-analysis can be considered as "an equally illlportant activity of 
interpreting and integrating the results of the empirical studies that 
have been done" (Fiske, 1983, p. 65). 
Meta-analysis in clinical medicine. Meta-analysis as a technique 
to integrate empiric research in clinical medicine has lagged behind 
the need. As evidence, in reviewing the first ten issues published in 
1982 of the New England Journal of Medicine, Journal of the American 
Medical Association, British Medical Journal, and Lancet, Halvorsen 
(cited in DerSimonian & laird, 1986) found only one of 589 articles 
that applied fonnal statistical methods to combine results. Mulrow-
( 1987) evaluated 50 review articles published between June, 1985 and 
June, 1986 in the Annals of Internal Medicine, Archives of Internal 
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Medicine, Journal of the American Medical Association, or New England 
Journal of Medicine. Although some degree of qualitative synthesis 
(e.g., describing differences in sa.Irple populations, intervention 
approaches, outcome measures) was attenpted in 43 of the 50 reviews, 
qualitative synthesis of the empiric research covered was attempted in 
only three. In an assessment of review articles published in Clinical 
Phannacy, Drug Intelligence and Clinical Phannacy, Drugs, and 
Phannacotherapy, Hendrickson and Amerson (1986) did not even include an 
analysis of the methcxlolcqies used in the reviews. Thus, it appears 
that not only is the primary literature lagging in the application of 
meta-analytical techniques, but some of the assessments of the review 
literature even fail to look for them. 
In 1987, sacks et al. published an evaluation of meta-analyses in 
clinical medicine to date. In their search for meta-analyses they 
discovered that although the first was published as early as 1955, only 
13 others were published during the subsequent 25 years. HDW'ever, they 
discovered an apparent new appreciation for meta-analysis beg"inning in 
1980 by finding 69 published between 1980 and 1987. 
Since meta-analysis has been only sparingly used in clinical 
medicine, there have been few assessments of them. Sacks et al. (1987) 
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evaluated 86 meta-analyses published in the clinical medicine 
literature meeting the inclusion requirement that at least one of the 
studies used in an individual meta-analysis be a rarrlomized controlled 
trial. F.ach meta-analysis was reviewed for study design, 
cornbinability, control and measurement of p::>tential bias, statistical 
analysis, sensitivity analysis, and application of results. 
'!he most notable aspect concerning the study design of the 
meta-analyses evaluated by Sacks et al. (1987) was the paucity of 
details provided. In only seven percent of the meta-analyses was the 
protocol described and in only 35% was the literature search strategy 
detailed. Although the studies included were rep::>rted in nearly all 
meta-analyses, a list of the studies excluded was rarely provided. 
Treatment assigrnnent (i.e. , rarrlamization) within included studies was 
described for most meta-analyses but few (22%) provided details 
concerning the ranges in patient, disease, and treatment 
characteristics across studies. 
Sacks et al. (1987) found that less than half (45%) of the 86 
meta-analyses evaluated described any differences that existed among 
studies included. Less common among the evaluated meta-analyses (20%) 
were statistical methodologies used to detennine homogeneity among 
included studies. 
overall, Sacks et al. (1987) found adequate control and 
measurement of p::>tential bias infrequently among the 86 evaluated 
meta-analyses. None rep::>rted details to ensure that methods and 
results were considered separately by the individual meta-analysts. 
In addition, in none were blinded data-extraction and measurement of 
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interobsel::ver agreement employed in conjunction. 
Adequate statistical methods for meta-analysis for the purpose of 
their evaluation was defined by Sacks et al. (1987) as "any reco:;Jlrized 
method of pooling except the sinple addition of successes across all 
trials to give an overall average" (p. 452). 'Ihose that reported only 
sinple addition of successes were considered "partial". Adequate 
statistical methods were used in 66% of the 86 evaluated meta-analyses. 
Consideration of 'fype I and 'fype II errors were acknowledged in 45% of 
the meta-analyses. Confidence intervals were reported in 43% and 
subgroup analyses were conducted in 63%. 
Among the 86 meta-analyses evaluated by Sacks et al. (1987), few 
sensitivity analyses were applied. Assessing the quality or making 
adjustments for differences in quality among studies in individual 
meta-analyses were discovered in only 19%. The issue of quality of 
individual studies was acknowledged in less than half (47%). Only 16% 
of the meta-analyses assessed the effects of different asst.nnptions, 
tests and criteria. While about 17 (20%) of the meta-analyses 
acknowledged the problem of publication bias, in only two were 
adjustments attempted. 
Sacks et al. (1987) found that the inplications of the 
meta-analyses as the authors saw them were included in 77%. However, 
economic considerations were only fully explored in one and addressed 
to a lesser degree in 17 (20%). 
overall, of the six major cat.eg"ories of meta-analyses assessed by 
Sacks et al. (1987), only 24 (28%) of the 86 addressed at least one 
issue in all six categories. Thirty-one (36%) addressed at least one 
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issue in five of the categories, 25 (29%) addressed four categories, 
five (6%) addressed three categories, and. one (1%) addressed two 
categories. 'Iberefore, although the use of meta-analysis is increasing 
in clinical medicine, methodologies and. quality vary considerably and. 
improvement is generally warrante:l. 
Using the same meta-analyses as Sacks et al. (1987), Chalmers et 
al. (1987b) assessed the degree by which meta-analyses of smaller 
controlled trials agreed with larger co-operative studies. A 
meta-analysis involving 12 studies of intravenous beta-adrenergic 
receptor antagonists for acute myocardial infarction in a total of 
4,408 patients produced similar results (i.e, confidence intervals of 
effect) as two separate large co-operative trials, one of which 
included 5, 778 patients and. the other 16,027. A meta-analysis of 
intravenous streptokinase for acute myocardial infarction involving 11 
randomized controlled trials and. a total of 5,268 patients resulte:l in 
a similar magnitude of effect as a large co-operative study involving 
11,712 patients; however, the confidence interval was narrower for the 
large co-operative study. Of interest in this comparison were the 
contrasting results of a particular~ analysis wherein the 
meta-analysis indicate:l a favorable effect from the treatment and. the 
large co-operative study indicate:l a favorable effect from the 
control. '!be other comparison of Chalmers et al. was that between a 
meta-analysis of the effect of phenobarbital for prevention of 
intracranial hemor:rhage in newborn infants involving seven studies and. 
a total of 413 patients with a co-operative study involving 280 
patients. '!be results differed; however, the confidence intervals 
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overlapped. 
Again using the same group of meta-analyses as Sacks et al. 
(1987), 01almers, Berrier, Sacks, Ievin, Reitman, and Nalgalingham 
(1987a) evaluated statistical and clinical agreement of meta-analyses 
concerning the same errpiric research. To the original 86 published. 
meta-analyses, five unpublished. meta-analyses were added.. Among the 91 
meta-analyses, 46 represented replicate analyses of 20 different 
treatments (i.e., 20 cohorts). The levels of statistical agreement 
were (a) experimental therapy significantly better (:g < .05), (b) trend 
in favor of experimental therapy (:g > .05), (c) no apparent statistical 
effect, (d) trend favoring control group(!?> .05), and (e) control 
group significantly better(!?< .05). The levels of clinical 
agreement were gauged. on the meta-analysis authors' enthusiasm and were 
(a) strongly favoring experimental therapy, (b) mod.erately favoring 
experimental therapy, (c) no difference of clinical interest, (d) 
moderately favoring control, and (e) strongly favoring control. The 20 
cohorts were divided. into two groups; one group in which all 
meta-analyses agreed within each cohort and another in which at least 
one meta-analysis within each cohort was in disagreement. This was 
done for both statistical and clinical scales. 
Among the 20 cohorts there was statistical agreement in 10 and 
disagreement in 10. Among the 10 cohorts in which there was 
statistical agreement, treatment was favored in eight. In the 10 
cohorts in which statistical disagreement existed., the disagreement was 
often between adjacent levels (e.g., l? < .05 and l? > .05); therefore, 
agreement in direction of effect often occurred despite statistical 
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disagreement. Clinical agreement was recorded for six of the 20 
cohorts. Of the six cohorts with clinical agreement, treatment was 
favored in five. As occurred with statistical disagreement, the 
rna.gnitude of clinical disagreement was typically adjacent levels. All 
six cohorts in clinical agreement were also in statistical agreement. 
No differences in agreement/disagreement status were observed within 
selected cohorts in which inclusion and exclusion criteria differed 
(e.g., meta-analyses including all published and unpublished research 
versus meta-analyses including only randomized controlled trials). 
Therefore, this preliminary evaluation of meta-analysis in clinical 
medicine indicates that there may be differences in the results between 
meta-analyses covering the same empirical research; however, the 
difference is usually in rna.gnitude and not direction. In addition, 
differences are more conuron to authors' interpretations of the results 
than statistical results. As concluded by the authors: 
Although this paper does not settle the question of whether meta-
analyses of clinical trials as now perfonned have sufficient 
scientific rigor to reveal reproducible facts, the process must 
continue in the future; hopefully, disagreements will disappear as 
meta-analyses methodology becomes more rigorous. The extent of 
agreement is encouraging, and, taken with the apparent lack of 
disagreement between results of meta-analyses of small trials 
compared with large, co-operative studies, suggest that one should 
not discourage, on the basis of their anticipated size alone, well 
designed and conducted small trials. (p. 740) 
The current need for meta-analysis rna.y soon become an 
expectation. The Ad Hoc: Working Group for Critical Appraisal of the 
Medical Literature (Mulrow, Thacker, & Pugh, 1988) recently published 
guidelines that call for meta-analytical techniques to be applied to 
reviews of medical literature. Einarson et al. (1985) have recormnended 
"that meta-analysis be used for drug reviews published in the pharmacy 
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literature" (p. 1962). 
Meta-analysis methcrlology. If the analogy of I..ouis, Fineberg, 
and Mosteller (1985) that "meta-analysis is to primary a research study 
as a primary research study is to its study subjects" (p. 1) is 
accepted, then conceptual approaches to empiric research can be applied 
to meta-analysis. 'Ihus, the typical steps required in conducting a 
meta-analysis include (a) defining a research question, (b} searching 
and retrieving relevant literature (i.e., subjects}, (c) defining 
inclusion and exclusion criteria, and screening the relevant literature 
retrieved (i.e, screening subjects}, (d} describing and analyzing the 
data, and (e} reporting and interpreting results (I..ouis et al., 1985; 
Thacker, 1988). 
The foundation upon which any meta-analysis is built is the 
clearly defined research question. Concerning research questions as 
they relate to clinical medicine, Yusuf (1987) advised that, "the 
question should always be framed in the context of the supposed 
mechanisms of drug action and the known epidemiology of that particular 
disease" (p. 281). All subsequent steps are necessarily related to the 
research question. In addition, covariates of interest also detennine 
subsequent methcrlological direction. 'Iherefore, no other steps towa:rd 
conducting a meta-analysis should be taken until the research question 
is clearly settled (Light, 1987; Thacker, 1988). 
'!he validity and generalizability of a completed meta-analysis is 
related, in part, to the degree in which the data relevant to the 
research question is covered. 'Iherefore, systematic processes to 
retrieve all relevant data are necessacy. 'Ihese data retrieval 
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processes include (a) electronic searches of appropriate databases 
(e.g., MEDLmE and Embase for clinical medicine literature), (b) manual 
searches through the reference sections of previously retrieved 
literature, and (c) contacting colleagues or other possible sources 
(e.g., govennne:ntal agencies, manufacturers) for unpublished 
infonnation ('!hacker, 1988). 
None of the methcxis used for meta-analysis directly address the 
choice of inclusion and exclusion criteria to be employed. The 
inclusion and exclusion criteria are dependent on the research question 
and researcher predispositions concerning what can and cannot be 
legitimately pooled (~ts, 1987). At present there are no accepted 
rules concerning the basic parameters that must be present for a 
particular study to be included in a meta-analysis. 'Ihis is a subject 
of continued debate among meta-analysts. The study parameters 
considered by meta-analysts acceptable for inclusion span a continuum 
from randomized controlled trials without confounding variables to all 
"relevant" studies (independent of fo:rm) including those considered 
flawed. Independent of the parameters by which the meta-analyst 
employs in selecting empiric data, it must be consistent and taken .into 
consideration when making .inferences from the results (Ll.ght, 1987) . 
There are many analytical methcxis used in meta-analyses. In 
general, there are two basic analytical approaches used. One is 
combfuing' significance levels and the other is combining magnitudes of 
effect (Strube & Harbna.nn, 1983). The fo:rm of the outcome data of 
interest and the amount of infonnation available dictate, in part, 
which analytical approach is employed. 
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Analyses that combine significance tests are generally used when 
little infonnation is provided in the errg;>iric research substrate. The 
basic premise of combining significance levels is "that it allows the 
reviewer to detennine whether a set of results could have arisen by 
chance" (st:rube & Hartmann, 1983, p. 15). There are several procedures 
used to combine statistical significance levels, some of which have 
been described by Hedges & Olk.in ( 1985, chap. 3) • These procedures are 
necessarily nonparametric and can be difficult to interpret. They only 
detennine whether a difference exists and provide no inf onnation in 
tenns of ma.gnitude of effect (Demets, 1987). 
A related approach to combining statistical significance levels 
knCMn as ''vote-counting" is based on the proportion of studies within a 
meta-analysis that reach statistical significance. A relationship 
between ind.ependent and dependent variables is considered significant 
if a "plurality" of studies reach statistical significance. Hedges and 
Olkin (1985, chap. 4) have criticized conventional vote-counting 
methods because of frequently insufficient power to detect snall 
differences even with large sample sizes. Hovvever, they have derived 
methods by which the vote-counting approach can be used to more 
accurately estimate the ma.gnitude of effect. Like combining 
statistical significance levels, the usefulness of vote-counting 
methods are restricted to situations where little infonnation is 
supplied in the errg;>iric research substrate. 
The two most connnon analytical approaches used in meta-analysis, 
particularly when two groups are co.rrpared, are effect size estimations 
and odds ratios. Effect size estimations are often used when the form 
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of the outcome variable of interest is continuous, whereas cdds ratios 
are useful when the outcome variable of interest is dichotomous 
(Dernets, 1987; strube & Harbnann, 1983). 
For meta-analyses in which the outcome variable of interest is 
continuous, effect sizes arrl confidence intervals are estimated for 
each study by using the standardized mean difference arrl asscx:::iated 
standard deviation, respectively (Hedges & olkin, 1985, chap. 5). An 
overall effect size arrl confidence interval can then be derived by 
averaging across individual studies after weighting them by appropriate 
factors (e.g., variance, quality) (Hedges & Olkin, 1985, chap. 6). 
For meta-analyses in which the outcome variable of interest is 
dichotomous, cdds ratios arrl asscx:::iated confidence intervals are 
derived for each study using the proportion of "successes" in one group 
over the proportion of successes in the comparison group. OOds ratios 
different than one indicate an effect arrl the distance from an cdds 
ratio of one indicates the magnitude of effect. overall cdds ratios 
arrl confidence intervals are also derived with weighting individual 
studies for the appropriate factors. 
It is assumed that effect sizes (when estimated by using 
standardized mean differences) arrl cdds ratios are the same across 
individual studies (fixed effect mcx:iel). This assumption of 
ho.mo::;eneity can be tested. Where heterogeneity of effect sizes or cdds 
ratios exist, outliers can be identified arrl procedures can be used to 
cluster groups of studies with hornoqeneous effect sizes or cdds ratios 
(Hedges & Olkin, 1985) • As an alternative, a random effects model 
could be used to account for the degree of heterogeneity (Hedges & 
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Olkin, 1985, chap. 9; DerSi.m:mian & laird, 1986). '!he irrportance of 
horoc>geneity amorq individual studies is an issue of debate amorq 
meta-analysts am is related to the debate concerning study parameters 
for inclusion into meta-analyses (Light, 1987). 
Irrlependent of the analytical methods used, the risk of 
publication bias usually exists. Publication bias refers to the 
dependency of meta-analyses on published literature that is generally 
selective for studies with positive results. Chan, Sacks, am 
Chalmers (1982) sw::veyed 291 authors of randomized clinical trials 
published in medical journals am found that 41% of the 141 responders 
had conducted unpublished studies. Amorq the randomized clinical 
trials conducted by the authors responding to the sw::vey, 77% of those 
reportirq positive results were published in contrast to 42% of those 
reportirq negative results beirq published. Therefore, the published 
literature on which a meta-analysis is based ma.y not be representative 
of all the relevant errpirical research (Begg, 1985). 
Methods have been proposed to account for publication bias. For 
situations in which a positive effect has been detected by a meta-
analysis, Rosenthal {1979) has derived a formula whereby the number of 
unpublished negative trials necessary to make the result of the 
meta-analysis null can be estima.ted. Similarly, L'Abbe et al. (1987) 
developed a method of quantifyirq publication bias by simulatirq either 
the sample size of one unpublished negative trial or the number of 
small negative trials (with a fixed sample size) that would be required 
to make the results of a positive meta-analysis negative. The 
estima.tes of Rosenthal am L'Abbe et al. are qualitative in nature in 
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that they provide a level of confidence in the positive results of a 
meta-analysis, i.e., if only a few negative \ID.published studies would 
make the results null there would be less confidence than if hundreds 
of unpublished negative trials would be necessary. In contrast, Begg 
(1985) derived a method whereby the magnitude of publication bias for 
each study in a meta-analysis is estimated in units of standard 
deviation relative to the true mean. While this method is more 
quantitative than those of Rosenthal and L'Abbe et al., it requires 
knowledge of the incidence of a specific occurrence (e.g., disease) and 
the total number of subjects possible (independent of consent to 
participate). Methods to determine. and adjust for negative publication 
bias have not been developed (L'Abbe, et al., 1987) 
Reporting results of meta-analyses is similar to reporting 
results of empirical research. However, detail to the descriptive 
aspects of the research substrate of a meta-analysis (empiric research) 
may have added importance for two reasons. One is that meta-analyses 
naturally accumulate research methods and procedures related to a 
particular research front that can be easily consulted by researchers 
investigating future en::ieavors. Another reason is that reviewers can 
more easily detennine the applicability of a meta-analysis from 
detailed descriptions (Strube & Hartmann, 1983). Graphical depictions, 
especially of effects size estimates and odds ratios with their 
associated confidence intervals are useful adj'lll1.cts to descriptions 
(Walker, Martin-Moreno, & Artalejo, 1988) • 
'Ihe interpretation of meta-analysis results is not a simple 
matter. Interpretations must take into account the general nature of 
meta-analyses. Iouis et al. (1985) emphasized this point by stating 
that: 
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Although the collection of papers leading to a meta-analysis might 
be based on experiments, observational studies, sample surveys, or 
other fonns of investigation, the meta-analysis itself is an 
observational study with the strengths and weaknesses associated 
with that design. (p. 2) 
Another ilnportant consideration is that from a "melange of 
treatments and mix of patients", quantitative estbnates are derived 
that are generally representative of average effects (Wittes, 1987, p. 
275) • 'Ihis is generally not a problem for policy makers such as 
insurance carriers and governmental agencies who are usually more 
interested in the types of average effects generated by meta-analyses. 
However, the quantitative estbnates with ''very high degrees of power 
does not gainsay the annoying reality that these estbnates of 'average' 
effects may be very difficult to apply to specific clinical problems" 
(p. 275) • 
It is difficult to resist the temptation among those in search of 
more specific inforrration to dredge the data within a meta-analysis. 
However, they do so at the risk of finding an apparent effect by chance 
that is not representative of the true effect (Collins et al., 1987). 
'!he peril of post hoc subgroup analysis was demonstrated in the ISIS-1 
trial (cited in Collins et al., 1987) of beta-adrenergic receptor 
antagonists in acute myocardial infarction. Subjects born und.er the 
astrological sign of scorpio benef itted more from the therapeutic 
intervention than those born und.er other astrological signs. 'Ihis 
result is more likely due to chance than any biological explanation. 
Peto (1987) has thus suggested that "most of the sul:;group analyses from 
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individual trials or from overviews of randomized trials should be just 
reported, but not believed" (p. 235), and Collins et al. (1987) 
suggest: 
Inference about the true size of any effects in subsets may be more 
reliable if based indirectly on an overview of all randomized 
patients in all trials, rather than on direct examination of only 
those subsets. (p. 249) 
For use in specific clinical situations, the infonnation derived from 
any given meta-analysis will rarely be decisive. The infonnation 
should be viewed in the context of a specific patient or a specific 
therapeutic regimen (Wittes, 1987). It provides some of the 
infonnation needed for specific clinical decisions (Yusuf, 1987). 
Roles of meta-analysis in clinical medicine. Meta-analysis plays 
many roles in clinical medicine. One of the roles meta-analysis plays 
is one of stabilization of treatment effects. If individual studies 
can va:ry from the true treatment effect as individual subjects can 
within a treatment group, meta-analyses can provide better estimates of 
the true effect as do group means derived from individual subjects. 
Similarly, meta-analyses can counterbalance any "overenthusiasm" that 
might be related to a particular outcome (Furberg & Morgan, 1987) • 
Meta-analysis has been particularly useful in evaluating moderate 
treatment effects. The large sample sizes necessary to detect moderate 
treatment effects often result in a series of studies that leave the 
research question unresolved. Properly conducted meta-analyses can 
provide adequate power to substantially reduce or eliminate the 
equivocation (DarSinonian & laird, 1986) • The Food a:nd Drug 
Administration used this approach in approving labelling for aspirin 
specifying that it could be used to reduce the risk of death in 
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specifying that it could be used to reduce the risk of death in 
patients 'Wllo had previously suffered an acute myocardial infarction. 
Individual studies had indicated that aspirin might confer such a 
benefit, but the effect was sufficiently moderate an:J the sample sizes 
sufficiently inadequate to reach statistical significance. However, a 
meta-analysis covering these studies subsequently confirmed the benefit 
of aspirin in patients previously experiencing acute myocardial 
infarction an:J the Food an:J Drug Administration acted on this 
infonnation (Furberg & Morgan, 1987; Hennekens, .Buring, & Hebert, 
1987). 
Similarly, meta-analysis can be used to analyze certain subgroups 
from an aggregate of studies not possible with individual studies. 
However, considering the danger in subgroup analysis as previously 
described, the use of meta-analysis for subgroup analysis should be 
reserved for those subgroups defined a priori. Where subgroups are 
identified in a meta-analysis by data dredging, they should only se:r:ve 
as topics for future research (Furberg & Morgan, 1987). 
Meta-analysis can an:J has been used in the planning of clinical 
trials (Hennekens et al, 1987) • Research questions can be generated 
from the results of meta-analyses. For example, in the meta-analysis 
of intravenous streptokinase for the treabnent of acute myocardial 
infarction (Yusuf et al., 1985), a reduction of mortality was recorded 
for patients 'Wllo received treabnent within 24 hours of symptom onset. 
Conventional wisdom at the time suggested that only those patients 
treated within four to six hours of syrrptom onset would benefit. To 
resolve this discrepancy, a large clinical trial was designed that 
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called for trea'bnent with streptokinase during the first 24 hours after 
onset of acute myocardial infarction synptam.s (ISIS-2, 1988). '!he 
results confinned the earlier meta-analysis in that benefits were 
recorded in all patients treated within 24 hours of synptom onset. 
In planning clinical trials, effect size estimates provided by 
meta-analyses can assist in estimating necessary sample sizes. 
Meta-analyses can prcxiuce more accurate estimates of effect size than 
pilot studies. '!his was illustrated by two studies assessing the 
effects of intravenous beta-adrenergic receptor antagonists in acute 
myocardial infarction. One of the studies based sample sizes on an 
earlier meta-analysis that suggested a 10% reduction in mortality was 
possible while the other study based sample sizes on a pilot study that 
suggested a 36% reduction in mortality. 'Iherefore, the sample sizes 
were substantially different and although each study resulted in the 
same ma.gnitude of effect (13-15% reduction in mortality), only the 
results of the study based on the meta-analysis reached statistical 
significance (Hennekens et al., 1987). 
Another role of meta-analysis is pennitting a view of "the forest 
through the trees" such that details or patterns that ma.y not have been 
discemable in any individual study can be highlighted (Furberg & 
Morgan, 1987). Similarly, meta-analyses can identify "gaps" in current 
knowledge, thereby exposing "weaknesses in the errpirical assessment of 
a given theory" (Strube & Hartmann, 1983, p. 23). 
Criticisms of meta-analysis. '!he recent introduction of 
meta-analysis as a fonnal method of research synthesis has not been 
universally embraced. [Eysenck (1978) has referred to it as 
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"mega.-silliness".) '!he criticisms can be divided into those that are 
of non-technical (i.e., enotional) origins and those of more technical 
(i.e., methodological) origins. 
Some of the non-technical abjections to meta-analysis are rooted 
in investigators' ownership of research findings and methodologies they 
used to derive them. It is difficult for some investigators to accept 
the fact that rarely do individual studies affect the long-range 
perspective of any particular paradigm. Meta-analyses serve to 
errphasize this principle as well as to question individual 
methodologies and underlying assumptions (Fiske, 1983; Glass & 
Reinhold, 1983). 'Iherefore, investigators unable to dispassionately 
view meta-analyses that include their work will likely reject them as a 
le;itimate undertaking. 
Among clinical medicine researchers, non-technical abjections to 
meta-analysis have been raised in the context of its effects on future 
research. Where a consensus has arisen with regard to a particular 
mode of therapy, a reluctance to submit subjects to investigations of 
alternatives can emerge. An example that has been cited (Yusuf, 1987) 
is the reluctance of some clinicians to enter post-menopausal women 
with Stage II breast cancer to chemotherapy regimens because of an 
existing consensus that tamoxifen (a non-chemotherapeutic agent) is 
effective even though these clinicians may be uncertain as to the best 
approach. 
Most of the objections and criticisms directed at meta-analysis 
are on methodological grounds and these primarily relate to the 
appropriateness of combining study populations, methodologies,· and 
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results, as well as using empiric research of varying quality (Glass & 
Kliegl, 1983; L'Abbe et al., 1987). Ct"itics have referred 
meta-analysis as comparing apples with oranges; hov.rever, the degree to 
which one considers this a significant problem depends on whether one 
is viewing the meta-analysis as one pertaining to apples, oranges, or 
fruit (Mintz, 1983). 
Integrating studies of different degrees of quality, and 
especially studies considered lov.r in quality, has generated debate as 
to the usefulness of meta-analysis. Eysenck (1978), in referring to 
the use of lov.r quality studies in meta-analyses, evoked an axiom used 
in the computer sciences, "gaibage in - ga:r:bage out". Hov.rever, the 
quality of studies can be taken into account by either specifying 
methodological requirements in the inclusion and exclusion criteria or 
by using quality as a covariate (L'Abbe et al., 1987). Olalmers, 
smith, Blackburn, Silvenran, Schroeder, Reitman, & Ambroz (1981) have 
developed a method by which the quality of a study can be quantified 
and weighted accordingly. 'Ihe seriousness of study design flaws could 
then be assessed by the degree in which they correlate with effect 
size. Glass and Kliegl (1983) have thus countered Eysenck's contention 
by suggesting that differences in study quality handled appropriately 
can result in "garbage in - information out". 
Pooling results of different studies using different 
methodologies, involving different subject types, and done at different 
times has long been debated among statisticians. 'Ibis debate has been 
appropriately extended by critics to meta-analysis. (Proponents of 
meta-analysis have suggested that narrative reviews suffer the.same 
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problems (Strube & Hartmann, 1983; '!hacker, 1988).] However, 
techniques such as sensitivity analysis and. weighted regression have 
been applied to meta-analyses to partially take the heterogeneity of 
methods, subjects, and. time into account (L'Abbe et al., 1987). 
Meta-analysis is still evolving and. methods to inprove methodological 
approaches that address same of the current limitations are under study 
('Ihacker, 1988). 
Slm:lmary. Meta-analysis refers to a group of methodologies that 
can be used to combine related empiric research to arrive at 
conclusions not possible by reviewing individual studies, or improving 
generalizations of individual studies. Meta-analysis is distinguished 
from the traditional narrative review in that statistical methodologies 
are applied to derive "objective" conclusions whereas narrative reviews 
are more subjective. However, meta-analysis is not a substitute for a 
definitive study in which conclusions are usually based on a more 
homogeneous sample than possible with a meta-analysis. Therefore, a 
major role of meta-analysis is where the appropriate definitive study 
is not logistically feasible or where there is uncertainty as to 
whether such a study is warranted. 
Meta-analysis is not without its critics; it is perhaps best 
described as an evolving entity. To assist the evolutionary process, 
L'Abbe et al., (1987) have suggested that a consensus conference be 
convened to develop stand.a.rd. protocols. They, among others (Stube & 
Hartmann, 1983), have also suggested that central registries of ongoing 
trials specific to well-defined content areas (such as the National 
Institutes of Health or World Health Organization for clinical 
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medicine) be establishe::i as a means to reduce the sarrpling bias known 
to plaque meta-analyses. In addition, brief summaries might be made 
available to assist investigators in assessing whether certain studies 
are relevant. ca.Ils have also been issue::i for continued investigation 
into statistical methods that will address the shortcomings of 
meta-analysis, development of methods to assess their quality, and 
better reporting of research reports (Strube & Harbnann, 1983; Thacker, 
1988). Strube & Harbnann have gone one step further in proposing "a 
generative function for meta-analysis that is an extension of the 
pre::iictive function" (p. 24) 
Although many important and useful meta-analyses relate::i to 
clinical medicine have been conducted, its acceptance in clinical 
medicine has been slO'iAT in coming. HO'iATever, the number of meta-analyses 
publishe::i related to clinical medicine is steadily increasing and 
there is evidence that meta-analytical techniques will eventually be 
require::i as :part of all literature reviews. 
METHOD 
General Approach 
'!he method by which the comparative nephrotoxicity of gentamicin 
and tobramycin was assessed. using previously completed studies centered 
on the meta-analytical concept of "effect size". Effect size generally 
represents the magnitudes of difference between pa.irs of trea'bnent 
conditions. '!bus, an effect size of zero suggests that there is no 
difference between a pa.ir of trea'bnent conditions (i.e., gentamicin and 
tobramycin nephrotoxicity) while an effect size of either less than or 
greater than zero suggests that a difference exists. '!he greater the 
effect size (independent of sign), the greater the magnitude of 
difference between trea'bnent pa.irs (Glass et al., 1981). 
'!here are several methods by which to estimate effect size. In 
the meta-analysis reported here, where the comparative nephrotoxicity 
of gentamicin and tobramycin could be evaluated with a continuous 
variable (i.e., degree of nephrotoxicity), effect sizes were estimated 
by directly calculating standardized mean differences (referred to in 
this pa.per as the parametric analysis) • Where the comparative 
nephrotoxicity could only be evaluated with a dichotomous variable 
(i.e., nephrotoxicity occurred or not), a modified vote-counting 
proce:::'iure was used to estimate effect sizes (Hedges & Olk.in, 1985). 
[Although Hedges and Olk.in refer to the mcx:lified vote-counting method 
as "pa.rtially parametric" (p. 47), in the meta-analytic procerlure 
reported here, it is referred. to as the nonparametric analysis.] 
overall, the meta-analysis of the comparative nephrotoxicity of 
gentamicin and tobramycin involved three distinct procedures. First, 
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searching and retrieving the relevant literature; second, screening 
the retrieved literature for inclusion and exclusion criteria; and 
third, analyzing the data in the literature :rrte!eting the screening 
criteria. 
Literature Search 
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Both electronic and manual searches of the medical literature 
were conducted to locate and retrieve published and unpublished studies 
related to the comparative nephrotoxicity of gentamicin and 
tobranwcin. In addition, the manufacturers of gentamicin (Schering, 
Inc.) and tobranwcin (Eli Lilly, Inc.) were contacted in order to 
retrieve any related unpublished infonration they might have had on 
file. 
Electronic literature search. MEDLINE [MEDIARS (Medical 
Literature Autorna.ted Retrieval System) online], International 
Fharmaceutical Abstracts (IPA), Embase, and Dissertation Abstracts 
Online were searched electronically. With the exception of 
Dissertation Abstracts Online, the published controlled vocabularies 
for each of the databases searched electronically were used to find the 
most appropriate te:rrns for the search strategy. All searches were 
limited to htnnan studies published in the English language. 
MEDLINE is an electronic database of predominantly clinical 
medicine literature produced by the National Library of Medicine. It 
is derived from approximately 3, 000 biomedical journals published 
worldwide beginning in 1966 (Kruse, 1983). '!he te:rrns used to search 
MEDLINE were, "kidney failure, acute" or "kidney tubular necrosis, 
acute" with both "gentamicin" and "tobranwcin11 (National Library of 
Medicine, 1987). 
Embase is an electronic database of predominantly clinical 
medicine literature produced by Elsevier Science Publishers. It is 
derive::i from approximately 4, ooo biomedical journals published 
worldwide since 1975 (Kruse, 1983). 'Ihe terms used to search Embase 
were, "acute renal failure" with both "gentamicin11 and "tobramycin" 
(E:x:cerpta Medic.a, 1984). 
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IPA is produced by the American Society of Hospital Fhannacists 
and is an electronic database derive::i from over 600 journals primarily 
relate::i to phannacy practice publishe::i worldwide since 1970 (Kruse, 
1983). The terms used to search IPA were, "kidney failure" with both 
"gentamicin" and "tobramycin" (Tousignaut, 1987) • 
Dissertation Abstracts Online is produced by Dissertation 
Abstracts International and is an electronic database comprised of 
nearly every doctoral dissertation dating back to 1860 (Perry, 1986). 
It was searc:he::i to determine whether relevant inforn:ation regarding the 
comparative nephrotoxicity of gentamicin and tobramycin has been 
subject of a doctoral dissertation that had not been otheJ::Wise 
publishe::i. The terms used for a free-text search of Dissertation 
Abstracts Online were, "gentamicin", "tobramycin", and 
"nephrotoxicity". 
Manual literature search. The manual literature search consisted 
primarily of scanning the reference lists of the studies retrieved from 
the electronic search. In addition, bibliographies provided by the 
drug manufacturers contacted were scanned for appropriate citations. 
Inclusion and Exclusion Criteria· 
'.Ihe inclusion criteria for entry of individual studies into the 
meta-analysis were different de:pending on the method used to estimate 
effect size. '.Ihe exclusion criteria were not similarly affected. 
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Parametric analvsis. '.Ihe criteria for the inclusion of studies 
that evaluated the ccnnparative nephrotoxicity of gentamicin and 
tobrarnycin using a continuous variable were (a) rnethcxis and results 
were in the English language; (b) investigations were limited to blil'!laJl 
subjects; (c) there were at least two inclependent groups in each study, 
one of which received gentamicin and the other tobrarnycin; (d) renal 
function was measured by either serum creatinine concentrations or 
creatinine clearances; and (e) means and measures of variance (i.e., 
standard deviation, standard error, variance, or range) of either 
continuous measure of renal function were reported. 
Sennn creatinine concentrations and creatinine clearances were 
the continuous variables selected as the basis for estimation of effect 
sizes because these have been the laboratory values most often used to 
measure nephrotoxicity in the ccnnparative studies involving gentamicin 
and tobrarnycin (Schentag, 1983). Creatinine is a metabolic prc:duct 
prcrluced in muscle that is released at a relatively constant rate. In 
the absence of renal failure, excretion of creatinine through the 
kidneys occurs at a rate (creatinine clearance) approxinately that of 
blcx:x:l filtered by the kidneys [glomerular filtration rate (GFR)]. 
'.Ihus, renal function or changes in renal function can be measured by 
creatinine clearance. I.og"istical considerations, however, frequently 
prohibit accurate measurement of creatinine clearance directly; 
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therefore, serum creatinine concenpation is often used. Since 
creatinine is produced at a relatively constant rate and is eliminated 
al.most entirely by excretion through the kidneys, a change in renal 
ftmction can be approximated by corresponding chan<Jes in serum 
creatinine (Ravel, 1978). Serum creatinine concentration and 
creatinine clearance are therefore necessarily related, and in fact, 
serum creatinine concentrations may be more sensitive to changes in 
renal function than creatinine clearance (Morgan, & Will, 1983). Both 
are considered. late markers of aminaglycoside nephrotoxicity (Schentag, 
1983). 
'!he exclusion criteria included (a) studies that included data 
reported in another study, and (b) studies not obtainable either 
directly or by available intra-libracy loan programs. 
Nonparametric analysis. '!he inclusion criteria for studies that 
compared the nephrotoxicity of gentamicin and tobramycin with a 
dichotomous variable were same as those for studies in the parametric 
analysis except that the incidence of nephrotoxicity for both the 
gentamicin groups and tobramycin groups had to be reported instead of a 
continuous measure of renal function. In addition, the definition of 
nephrotoxicity used had to be specified. '!he exclusion criteria were 
the same as those for studies in the parametric analysis. 
Da.ta Collection 
From the lists of references available as a result of the 
literature searches, studies were identified that appeared related to 
the comparative nephrotoxicity of gentamicin and tobramycin. 'Ihese 
references were obtained and screened according to the inclusion and 
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exclusion criteria. 'Ihose studies. that met the screening criteria were 
entered into the meta-analysis and se:parated into (a) studies to be 
used for the parametric analyses, (b) studies to be used for the 
nonparametric analyses, and (c) studies that could be used for both the 
parametric and nonparametric analyses. 
Data Analysis 
Parametric analysis. 'Ihe estimated effect size for each study 
that met the screening criteria for studies that compared gentamicin 
and tobramycin nephrotoxicity using a continuous measure of renal 
function was derived by the standardized mean difference, 
(_xG - XT) /§, 
'Where _xG and XT are the mean continuous measures of renal function 
(serum creatinine concentration or creatinine clearance) for the 
gentamicin and tobramycin groups, respectively, and § is the pooled 
sarrple standard deviation as derived by, 
(1) 
§= 
(DG _ 1) (§G)2 + (DT _ l) (§T)2 
DG + DT - 2 
(2) 
'Where nG and nT are the gentamicin and tobramycin group sample sizes, 
respectively, and §G and §T are the standard deviations of the 
continuous measures of renal functions for the gentamicin and 
tobramycin groups, respectively. Pooled estimates of sarrple standard 
deviations were used because equal PJpulation variances for the 
gentamicin and tobramycin groups could be assumed. (Hedges & Olk.in, 
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1985, pp. 78-79). Where the range of :measurements of renal function 
were providerl in place of standard deviations, the standard deviation 
was approximaterl by§ = rarqerJij. Where the standard error of the 
renal function :measurements were providerl in place of the standard 
deviation, the standard deviation was deriverl by§ = standard error -{D 
(Littenberg, 1988). 
'Ihe estimate of effect size as derived by F.quation 1 is 
associaterl with a small sample bias approx:imaterl by 3cJ/(4N - 9); thus, 
as the sample size increases, the bias is reduced. To adjust for this 
bias, the effect size deriverl by F.quation 1 was multiplierl by the 
correction factor J(!l!) = (1 - (3/{4!1! - l})], where !l! = [(DT + DG) - 2] 
(Herlges & Olkin, 1985, pp. 79-80). 'Ihus, the effect size (g) for each 
study was estimaterl by 
g = (J!l)) 
'Ihe large sample distribution of F.quation 3 approximates 
nonnality if nG and nT increase at the same rate. 'Ihe estimaterl 
variance of g is thus, 
a-2 (g) = + 
and the 95% confidence intervals are then, 
cJ u = 9 + c cv/2 G(9) , 
(3) 
( 4) 
(5) 
'Where '1 is the population effect size estimaterl by g and C «/2 is the 
two-tailerl critical value of the standard nonnal distribution (Herlges & 
Olk.in, 1985, pp. 85-88). 
Therefore, according to Equation 3, an estimated effect size 
greater than zero suggests that gentamicin is associated with 
nephrotoxicity to a greater degree than tobramycin. Conversely, an 
estimated effect size less than zero suggests that tobramycin is 
associated with nephrotoxicity to a greater degree than gentamicin. 
Otherwise an estimated effect size approximating zero suggests that 
there is no significant difference in the degree of nephrotoxicity 
between the two agents. 
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Confidence intervals can also be used for interpretation. A 95% 
confidence interval as derived by F.quation 5 that is comprised of 
values only greater than zero suggests that gentamicin is associated 
with nephrotoxicity to a greater degree than tobramycin. Conversely, a 
95% confidence interval comprised of only values less than zero 
suggests that tobramycin is associated with nephrotoxicity to a greater 
degree. Other-wise, 95% confidence intervals that include zero 
suggest that there is no significant difference in the degree of 
nephrotoxicity between the two agents. 
To derive an estimated effect size for the series of comparative 
trials, a weighted linear combination of the individual effect sizes 
was used (.9v, = 11).91 + •.. + ~k, where 111 •.• !Y'}{ are nonnegative 
weights summing to unity). Weights were assigned based on the inverse 
of the effect size variances, 
(6) 
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'Ihe weighted estimate of J + (.9+) based on the sarrple estimate of c) (g) 
to derive the weights for each study was 
(7) 
(Hedges & olkin, 1985, pp. 109-111). 
Like the effect size estimates for individual studies, the 
weighted effect size estimate for the series of studies (.9+) 
approximates nonnality; thus, confidence intervals forJ' + can J::e 
derived using g+, assuming nT and nG increase in size at the same rate. 
'Ihe confidence intervals for the estimated effect size for the series 
of studies were then, 
cJ L = .9+ - C d./2 ~ (.9+) ' J u = .9+ + c d./2 6 (.9+) ' 
where C # 2 is the two-tailed critical value of the standard nonnal 
distribution and G~.9+) is derived by 
0- 2(d+) ~ ( i .,_1 . )-1 ~"'' (j (91) 
(Hedges & olkin, 1985, pp. 112-113). 
'Iherefore, like estimations of effect size for individual 
studies, an estimated effect size for the series of studies that is 
greater than zero suggests that gentamicin is associated with 
(8) 
(9) 
nephrotoxicity to a greater degree than tobramycin, and conversely, an 
estimated effect size less than zero suggests that tobramycin is 
associated with nephrotoxicity to a greater degree than gentamicin. 
otherwise, estimated effect sizes approximating zero suggest there is 
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no significant difference in the degree of nephrotoxicity between the 
two agents. 
Confidence intervals can be used to make similar 
interpretations. A 95% confidence interval carrprised of only values 
greater than zero suggests that gentamicin is associated with 
nephrotoxicity to a greater extent than tobramycin and an estimated 
effect size 95% confidence interval carrprised of only values less than 
zero suggests that tobramycin is associated with nephrotoxicity to a 
greater extent than gentamicin. otherwise, 95% confidence intervals 
that include zero suggest no significant difference in the degree of 
nephrotoxicity between the two agents. 
In order to make inferences from the aggregate effect size 
estimate, (Q+), the assumption of homogeneity of effect sizes among the 
population effect sizes nrust be met (i.e., cJ 1 =J 2 = ... =Jk>. 
Hamcx;Jeneity of effect sizes was tested by using the Q statistic, 
k 
L (gi - Q.+)2 Q = --'* 2(d·) ,.t .. 1 v -1 (10) 
wherein Q has an asyrrptotic chi-square distribution with k-1 degrees of 
freedom when there is homogeneity of population effect sizes in the 
series of k studies. Therefore, if Q exceeds the .05 percent critical 
value of the chi-square distribution with k-1 degrees of freedom, the 
null hypothesis of homogeneous population effect sizes is rejected 
(Hedges & olkin, 1985, pp. 122-123). A group of homogeneous studies 
was identified by withdrawing studies until the homogeneity assumption 
was met as defined by the Q statistic. 
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Sensitivity analyses were conducted to detennine the relationship 
of certain variables with estimated effect size. '!he effect of 
hOillCXJeneity on the overall effect size estimate was detennined. by 
with-drawing individual studies until hOillCXJeneity was satisfied. by the 
Q statistic. Relationships of individual study characteristics with 
estimated. effect size were investigated using sirrq;>le linear regression 
techniques (God.frey, 1985) with Systat (Wilkinson, 1985). Independent 
variables selected. were those in which differences of clinical 
significance existed between the gentamicin and tobramycin groups and 
included. mean age, mean durations of therapy, initial renal function, 
and incremental changes in renal function. In addition, whether the 
studies were blinded. or randomized. was investigated as well. 'Ibe 
regression analyses were restricted. to the hOillCXJeneous group of 
studies. 
Nonparametric analysis. 'Ihe dichotomous variable used. in studies 
comparing the nephrotoxicity of gentamicin and tobramycin was whether 
nephrotoxicity occurred. or not according to arbitrary criteria. To 
estimate the effect size of the difference in nephrotoxicity of 
gentamicin and tobramycin in this series of studies, the :mcd.ified. 
vote-counting method of Hedges and Olk.in (1985, chap. 4) was employed.. 
'Ibis method is based on the proportion of studies within a series of k 
studies in which the difference between groups reach statistical 
significance. 
To estimate the effect size of a series of k studies using the 
vote-counting method of Hed.ges and Olk.in (1985, chap. 4), each group 
within each study and between studies must be equal in size, (i.e, the 
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number of patients in the gentamicin group must be equal to the number 
of patients in the tobramycin group arrl all studies must have the same 
numbers of patients in each treatment group) • However, an average 
value can be derived using the square mean rcx:>t (SMR), 
(11) 
where n is the equivalent sample size in each treatment group arrl k is 
the number of studies in the series (Hedges & Olkin, 1985, pp. 67-69). 
The mcxtif ied vote-counting method to estimate effect size also 
requires that differences between groups were tested statistically by 
using the .t distribution. To satisfy this criteria, the differences in 
proportions of patients considered nephrotoxic in the gentamicin group 
versus the tobramycin group in each study were tested statistically 
using the Relative Deviate Test which prOO.uced z scores (O'Brien & 
Sharnpo, 1981). Since the average sample size (DSMR) exceeded 30, the£! 
distribution approximates the t distribution. A difference reaching a 
critical z score of 1.96 (.p = .05, two-tailed) was considered 
statistically significant. 
The estimated effect size of the difference in gentamicin arrl 
tobramycin nephrotoxicity based on the proportions of patients 
considered nephrotoxic was derived by 
... 
P.os<e> = ufk, (12) 
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where U/k is the proportion of studies in which the difference between 
the gentamicin and. tobramaycin groups reached statistical significance 
at the .05 level (Hedges & Olk.in, 1985, pp. 52-53). A table giving 
.... 
P.05(8) as a function of effect size and. the corrnnon sample size (DSMR) 
was used to derive the estimated effect size for the series of studies 
(pp. 60-61) • 
Confidence intervals for the proportion of studies in which the 
difference between the two treatment groups reach statistical 
significance at the • 05 level were computed by, 
- /£(1 - §) 
Pr. = ~ - c oly'2 v . 
k 
I; ~(1 - p) 
Pu = p + c J./2 v- k , 
where p is the proportion of studies in which the difference in 
(13) 
proportion of gentamicin and. tobramycin patients considered nephrotoxic 
reached statistical significance, c o<fl is the two-tailed critical 
value for the stand.ard normal distribution, and. k is the number of 
studies in the series (Hedges & Olkin, 1985, p. 54) From these values, 
the same table used to derive the mean estimated effect size is used to 
derive the estimated effect size confidence interval. 
Because with this method an effect size can be estimated only for 
a series of studies, sensitivity analyses ilwolving relationships of 
individual study characteristics with estimated effect size cannot be 
.ilwestigated. Hc:Mever, the effect of specific studies on the study 
series estimated effect size was .ilwestigated by removing individual 
studies or grouping others. 
RESUI1I'S AND CONCI.DSIONS 
Literature Searches 
The literature searches identified. 36 studies in which the 
nephrotoxicity associated. with gentamicin and tobramycin was compared.. 
After retrieval and screening each study according to the inclusion and 
exclusion criteria, 18 (50%) were eligible for analysis. All of the 
studies were published. between 1976 and 1985 (Table 1). 
Among the clinic.al trials that were not included. in the 
analysis, three were excluded. because they were not comparative, four 
because renal function was not assessed, one because neither a 
continuous measure of renal function nor the proportion of patients 
considered nephrotoxic were reported., and eight because the same data 
were reported. in other studies included. in the analysis. In addition, 
one study identified. was not obtainable and one was not published. in 
the Eng'lish language. 
Descriptive Data 
Of the 18 studies included. in the analyses (Table 1), 11 provided 
documentation of renal function sufficient for the parametric analyses 
(i.e., 10 reporting sennn creatinine concentration and one creatinine 
clearance). Two of these studies were derived. from one published. 
article (Matzke, Iucarotti, & Shapiro, 1983) • 'IWo separate independent 
investigations were conducted. in this study; and therefore, represent 
two of the 18 studies included. in the meta-analysis (Study 10 and Study 
11). Seven of the studies provided. only enough infonnation for the 
nonparametric analyses. However, six of the studies included. in the 
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Table 1 
Clinical Trials Included in Analysis 
Study 
N\.:aTber 
First 
Author 
Year 
Published Source 
Clinical Trials Included Cilly in Pararretric Analysis 
1 Madsen 1976 Jarrnal of Infectious Disease 
2 Kahlneter 1978 Journal of Antimicrobial Chem::rt:her?PY 
3 Goodwin 1979 Proceedings of 11th International Congress of 
Cherotherapy 
4 Itsarayoun:JyUen 1982 Pediatric Pharmacology 
5 Don ta 1985 Antimicrobial Agents and Charotherapy 
Table continued 
Table 1 (continued) 
Clinical Trials Included in .Analysis 
Study 
Nmber 
First 
Author 
Year 
Published Source 
Clinical Trials Included in Both Parairetic and Nonparairetic .Analyses 
6 Smith 1980 New Englarrl Joornal of Medicine 
7 FOI¥J' 1981 Journal of Ant:imicrcbial Otarotherapy 
8 Schentag 1981 Antiroicrcbial ~ents and Otarotherapy 
9 Feig 1982 Journal of Anti.micrcbial Otarotheraei: 
10 Matzke (A)a 1983 Anerican Journal of Ne}'.:hrology 
11 Matzke (B)a 1983 Anerican Journal of Ne:Efu:ology 
Table continued 
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Table 1 (o::intinued) 
Clinical Trials Included in Analysis 
Sbxly 
Nmber 
12 
13 
14 
15 
16 
17 
18 
First 
.Author 
Year 
Published Source 
Clinical Trials Included in Only Nonpararretric Analysis 
Walker 1976 Journal of Infectious Disease 
Wade 1978 Lancet 
Kunin 1980 Joornal of the hrerican Medical Association 
Keys 1981 Mayo Clinic Pr~s 
Brown 1982 Antimicrobial Agents and Olarotherapy 
Panrorl:x:> 1982 Biq::hannaceutics and Drug Distribution 
Fee 1983 Review of Infectious Disease 
~ Matzke stuiy iocluded b.io separate analyses and are thus labeled as Matzke 
(A) and Matzke (B) , respectively. 
1.11 
I-' 
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para-metric analysis also provided. the proportions of patients 
considered. nephrotoxic in each treatment group so these studies were 
also included. in the nonparametric analysis. 'lli.erefore, a total of 13 
clinical trials were included. in the nonparametric analyses. 
'lli.e 18 studies included. in the meta-analysis involved. a total of 
967 treatment courses of gentamicin and 876 treatment courses of 
tobramycin. Of the 11 studies used in the parametric analyses, there 
were 525 courses of gentamicin and 523 courses of tobramycin. Of the 
seven clinical trials that could only be used for the nonparametric 
analyses, there were 442 courses of gentamicin and 353 courses of 
tobramycin. When the clinical trials that could be used for both 
analyses were combined. with those that could only be used for the 
nonparametric analyses, there were 862 courses of gentamicin and 758 
courses of tobramycin. 
As shCMn in Table 2, the sample sizes were generally equivalent 
in each treatment group for nearly all the clinical trials included. in 
the analyses. 'lli.e two exceptions were Study 4 (Itsarayoungyuen, Riff, 
Schauf, Hamilton et al., 1982), and Study 17 (Pancorbo, Compty, & 
Heissler, 1984). In Study 4, 20 patients received. gentamicin and 30 
patients received. tobramycin due to a randomization scheme designed. to 
assign patients to gentamicin or tobramycin in a 2: 3 ratio. 'lli.e basis 
for this randomization scheme was that because gentamicin had been 
previously studied. more extensively in the patient population 
randomized. (neonates), it was desirable to randomize more patients 
into the tobramycin group. In Study 17, 125 patients received. 
gentamicin and 39 patients received. tobramycin. In this study, 
Table 2 
Descriptive Data of Clinical Trials Included in Analyses 
To~ 
Dose Seruip Cone. 
G T G T 
Clinical Trials Included cnly in Pararretric Analysis 
1 36 36 mt1 NR NR NR 7 7 NR NR 
2 18 19 59 67 3.68 2.57 21 15 NR NR 
3 22 22 NR NR 2.32 2.88 15 15 2.1 2.2 
4 20 30 0.004 0.004 0.67 0.6B 8 B NR NR 
5 9 11 55 59 2.05 2.60 9 9 NR NR 
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Table 2 (continued) 
Descriptive Data of Clinical Trials Included in Analyses 
Pati~t 
hje 
G T 
Tota~ 
Dose 
G T 
~ Cone. 
G T 
Clinical Trials Included in Both Parametic and Nonpa.rametic Analyses 
6 72 74 5B 59 1.90 1.92 6 6 2.8 2.5 150 
7 102 103 51 55 1.99 1.83 B 8 1.6 1.3 BB 
8 137 121 67 66 1. 70 1.70 10 11 1.6 1.4 51* 
9 25 29 57 57 NR NR 8 9 1.1 1.4 85 
10 49 49 61 64 1.73 1.81 10 11 1.4 1. 7 95 
11 50 48 62 62 1.99 1.98 10 11 1.4 1.5 109 
Table oontimled 
159 
97 
51 
7B 
104 
103 
Table 2 (continued) 
Descriptive Data of Clinical Trials Included in Analysis 
12 40 40 
13 43 47 
14 29 33 
15 15 12 
16 103 96 
17 125 39 
18 87 86 
Pati~t 
h:je 
G T 
Totati 
Dose 
G T 
Sennp 
Cone. 
G T 
Clinical Trials Included in Only Nonpararretric Analysis 
NR/NSi NR/NS NR NR 7 7 NR NR 
NR NR NR NR NR NR NR NR 
55 57 2.1 2.2 10 11 NR NR 
51 45 NR NR 19 14 1.6 1.9 
NR NR NR NR NR NR NR NR 
59 59 1. 7 1.8 9 10 1.4 1.2 
44 46 1.9 2.4 9 11 1.0 0.9 
Creatinineg 
G T 
NR NR 
NR NR 
NR NR 
NR NR 
NR NR 
128 131 
NR NR 
8G = gentamicin. b.r = t.oQramycin. ~ age in years. ~ total dose in grams. 
Tuan duration in days. ~ trough serum concentrations in milligrams/liter. 
9Mean serum creatinine (milligraws/liter) except for Stud¥ 8 which is creatinine 
clearance (milliliters/minute). A'NR = data not reported. ""NR/NS = data not reported but 
difference described as not statistically significant. Ln 01 
patients we.re not assigned to receive gentamicin or tobramycin by 
random allocation. 'lbe drug prescribed was detennined by the prima:ry 
care physician and at the time of this study, the.re was an apparent 
preference for gentamicin at the institution where this study was 
conducted.. 
'lbe mean patient age was reported for both the gentamicin and 
tobramycin groups in 13 studies (72%). Although the mean patient age 
for both grou,ps was not reported in Study 12 (Walker & Gentry, 1976), 
it was noted that the difference in ages did not reach statistical 
significance. With exception of Study 4 (Itsarayoungyuen et al., 
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1982), which involved neonates, all the studies involved mostly adults. 
'lbe mean patient ages for both treabnent grou,ps generally occurred in 
the fifth to seventh decades. Within the studies in which mean patient 
ages we.re reported, mean ages we.re always similar for the gentamicin 
and tobramycin grou,ps (Table 2) . 
'lbe mean total amount of gentamicin and tobramycin used was 
recorded in 12 studies (67%). Excluding Study 4 (Itsarayoungyuen et 
al. , 1982) , which involved neonates, the mean total amounts of 
gentamicin and tobramycin used ra.ng-ed from 1.69 to 3.68 grams and 1.70 
to 2.88 grams, respectively. Within the studies reporting the mean 
amount of gentamicin and tobramycin used, the amounts were very similar 
for each group with the exception of two studies. In Study 2 
(Kahlmeter, Hallberg, & Kanune, 1978), the mean total dose of 
gentamicin was 3.68 grams carrpared to 2.57 grams of tobramycin. In 
Study 18 (Fee, Vierra, & lathrop, 1978) , the mean total dose of 
gentamicin was 1. 9 grams carrpared to 2. 4 grams of tobramycin (Table 2) . 
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'!he mean duration of gentamicin and tobramycin therapy was 
reported in 16 studies (89%). '!he mean duration of therapy ra.J1<:1ed from 
six to 21 days and six to 15 days for gentamicin and tobramycin, 
respectively. With the exception of two studies, the mean duration of 
therapy for gentamicin and tobramycin were nearly identical. For lx>th 
exceptions, gentamicin was used for a longer period of time than 
tobramycin. In Study 2 (Kahl.meter, Hallberg, & Karnrne, 1978), mean 
gentamicin use duration was 21 days as compared to a mean of 15 days 
for tobramycin use. In Study 15 (Keys, Kurtz, Jones, & Muller, 1981), 
mean gentamicin use duration was 19 days compared to a mean of 14 days 
for tobramycin use. In Study 2, the longer mean duration of therapy 
for gentamicin correlated with the larger mean total dose reported. 
Mean total dose for Study 15 was not reported (Table 2) • 
Mean trough gentamicin and tobramycin serum concentrations were 
reported in 10 studies ( 56%) • Mean trough serum concentrations in the 
studies in which they were reported ra.J1<:1ed from 1.0 to 2.8 milligrams/ 
liter and 0.9 to 2.5 milligrams/liter for gentamicin and tobramycin, 
respectively. Within each reporting study, the gentamicin and 
tobramycin trough serum concentrations were very similar (Table 2) . 
'!he mean serum creatinine concentrations prior to initiation of 
therapy were reported for lx>th the gentamicin and tobramycin groups in 
11 studies (61%) and the mean creatinine clearance prior to initiation 
of therapy was reported in one (6%). '!he mean initial sen.nn creatinine 
concentration ra.J1<:1ed from 79 to 177 micromoles/liter and 78 to 159 
micromoles/liter in the gentamicin and tobramycin groups, respectively. 
Within each of the reporting studies, initial serum creatinine 
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concentrations were similar for both gentamicin and tobramycin groups 
with the exception of Study 5 (D:>nta & Lembke, 1985) in 'Which the 
initial serum creatinine concentration for the gentamicin group was 177 
micromoles/ liter corrpared to 108 micromoles/liter for the tobramycin 
group. Sen.mt creatinine concentrations considered to be indicative of 
nonna.l renal function range from 71 to 177 micromoles/liter (Ravel, 
1978). Only the gentamicin group in Study 5 reached. the upper limit. 
In study 8 (Schentag, Plaut, & Cerra, 1981) creatinine clearance 
was used. instead of serum creatinine concentrations. 'Ihe initial 
creatinine clearance for both the gentamicin and tobramycin groups was 
51 milliliters/minute (Table 2). Creatinine clearances indicative of 
nonna.l renal function are between 90 and 120 milliliters/minute; 
however, nonna.l values decrease with age (Ravel, 1978). 'Ihus, Study 8 
differed. from the others in that both groups had compromised renal 
function at the initiation of therapy. 'Ibis is consistent with the 
greater severity of illness among the patients in Study 8 than the 
other studies. 
'!he incidence of neph:rotoxicity for each treatment group was 
recorded. in each of the 13 studies included. in the nonparametric 
analysis according to the definition of neph:rotoxicity established. by 
the investigators of each study. 'Ihe definitions of neph:rotoxicity 
used. in each of these studies are listed. in Table 3. Al though the 
definitions varied. among studies, they were generally similar. 
Arong the 13 studies included. in the nonparametric analysis 
(Table 4), the neph:rotoxicity incidence ranged. from 4 to 55% and 2.5 to 
58% for the gentamicin and tobrarnycin groups, respectively. 'Ihe 
Table 3 
Definitions of Netfu:ot.oxicity in Nonpararretric Analysis 
Sttrly 
Nurrber Definition of Neffuotoxicity 
Stu:ties Included in Both Pararretic and Nonpararretic Analyses 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
SCRa increase > 44 if initial SCR < 265 or, 
SCR increase >-88 if initial SCR > 265 
SCR increase > 44 if initial SCR < 265 or, 
SCR increase } 88 if initial SCR > 265 
SCR increase > 44 
SCR increase > 27 
SCR increase > 44 if initial SCR < 177 or, 
SCR increase> 30% if initial SCR > 177 
SCR increase > 44 if initial SCR < 177 or, 
SCR increase} 30% if initial SCR > 177 
Studies Inclooed in cnly Nonpararretric Analysis 
SCR increase 
SCR increase > 35 if initial SCR < 265 or, 
SCR increase } 80 if initial SCR > 265 
SCR increase > 33% 
Iothalama.te decrease to < 14% of initial 
SCR increase > 35 
SCR increase > 30% 
Final SCR > 133 with decrease in CRCL > 33% 
or, SCR increase> 88 if initial "abnonnal" 
~CR = serum creatinine c:onoantratian in micraroles per liter. 
CRCL = creatinine clearance in milliliters per minute. 
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Table 4 
ca:rponents of Nonparametric Bf feet Size Esti.ma.tions 
Study 
Nurri:ler Z-Score 
Difference 
Statistically 
Significant 
Stu:lies Included in Both Pararnetic and Nonpa.rarnetic Analyses 
6 19/72 9/74 2.8 Yes 
7 8/102 7/103 0.3 No 
8 51/137 27/121 2.5 Yes 
9 10/25 8/29 1.0 No, 
10 5/49 9/49 -1.1 No 
11 4/50 8/48 -1.3 No 
Stt:rlies Included in Only Nonparametric Analyses 
12 7/40 2/40 1.8 No 
13 13/43 11/47 0.8 No 
14 16/29 5/33 3.3 Yes 
15 6/13 7/12 -0.9 No 
16 5/103 2/96 1.1 No 
17 5/125 1/39 0.4 No 
18 22/87 13/86 1.8 No 
~of ~'!=ients neph;:ota>d.c/total.nunt:er of patients. 
G = gentamicin group •.. '""l.' = t.obrarqyci.n group. 
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incidence of nephrotoxicity was lower for the gentamicin group in three 
of the studies and higherin the other 10. 'Ihe difference in the 
incidence of nephrotoxicity between groups reached statistical 
significance in three studies, in all of which a lower incidence was 
recorded for the tobramycin groups. 'Ihe greatest differential between 
the two groups in any one study was recorded in Study 14 (Kum.in, 1980) 
in which the incidence of nephrotoxicity for the tobramycin group was 
15% corrpared to 55% for the gentamicin group. 
'Ihe ranges of nephrotoxicity for both groups remained the same 
when the seven studies that could only be used in the nonparametric 
analysis were considered. In only one study was the incidence of 
nephrotoxicity lower for gentamicin than tobramycin. Also in only one 
study did the difference in the incidence of nephrotoxicity between the 
treatment groups reach statistical significance (Table 4). 
Parametric Analyses 
Effect size estimations. 'Ihe corrp:ments used to estimate effect 
sizes for each study based on a continuous measure of renal function 
are listed in Table 5. 'Ihe estimated effect sizes derived, and their 
respective variance terms (stan:iard deviations and 95% confidence 
intervals), are listed in Table 6. Figure 1 is a plot of the estimated 
effect sizes and associated 95% confidence intervals for each study. 
'Ihe estimated effect sizes ranged from -o. 887 to 1. 666. Four of 
the 11 studies were associated with estimated effect sizes of negative 
values (suggestin:';J tobramycin is associated with nephrotoxicity to a 
greater degree than gentamicin) and the remainin:';J seven studies were 
associated with estimated effect sizes of positive values (suggesti.:n;J 
Table 5 
Carponents of Effect Size calculations in Pararretric Analysis 
Study 
Nuni:er 
1 
2 
3 
4 
5 
6 
7 
ad 
9 
10 
11 
114 111 
100 109 
323 157 
124 88 
207 126 
186 168 
203 230 
41 50 
100 78 
125 134 
148 149 
St:an:Ja:cd 
Deviation 
G T 
26.5 26.5 
15.2 31.0 
133.3 38.8 
39./5 48.4 
275.7 59.7 
150.2 152.3 
28.0 31.3 
27.0 34.0 
43.3 23.9 
40.4 35.4 
30.0 122.5 
Pooled 
Staxxla:rd 
Deviation 
25.5 
24.6 
98.l 
45.1 
189.1 
151.2 
29.8 
30.S 
35.0 
38.0 
88.3 
Correction 
Factor 
[J(m) J 
0.989 
0.978 
0.982 
0.984 
0.958 
0.995 
0.996 
0.997 
0.957 
0.992 
0.992 
~tial s~ creatinins! concentratic;ms in miC!)pO~~/liter. 
G = gentamicin group. ,. = tabrareycin group. ""Initial 
creatinine clearance in milliliters/minute. 
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Table 6 
Estimated Effect Sizes in Pararretric Analysis 
Study 
Nurcber 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Estimated 
Effect Standard 
Size Deviation 
0.131 0.236 
-0.334 0.331 
1.666 0.350 
0.772 0.300 
0.420 0.454 
0.116 0.166 
-0.887 0.146 
0.294 0.125 
0.605 0.457 
-0.233 0.203 
-0.020 0.202 
0.007 0.063 
95% Confidence Interval 
-0.332 - 0.593 
-0.983 - 0.316 
0.980 - 2.352 
0.187 - 1.358 
-0.480 - 1.300 
-0.201 - o. 4.40 
-1.160 - -0.332 
0.049 - 0.540 
-0.291 - 1.502 
-0.630 - 0.165 
-0.416 - 0.376 
-0.116 - 0.131 
~ighted by inverse of estirna.ted effect size variance. 
63 
Figure 1. Effect Size Estimates rn Parametric Analysis. 
Study 
11 
10 
9 
a 
7 
J 
2 
-1.25 -1.0 -o.1s -o.5 -0.25 o 0.25 o.:s o.n i.o 1.2:s 1.5 1.7:s 2.0 2.25 2.:s 
Effect Size 
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gentamicin is associated with nephrotoxicity to a greater degree 
than tobramycin). 
65 
The standard deviations of the estimated effect sizes ranged from 
0.125 to 0.457. The widest 95% confidence interval was 1.81 and the 
narrowest was 0.26 (Figure 1). '!he 95% confidence intervals included 
zero for seven studies (suggesting no difference in the degree of 
nephrotoxicity associated with gentamicin and tobramycin). Of the four 
studies in which the 95% confidence intervals did not include zero, 
three enconpassed only positive values (suggesting gentamicin is 
associated with nephrotoxicity to a greater degree than tobramycin) and 
one encompassed only negative values (suggesting tobramycin is 
associated with nephrotoxicity to a greater degree than tobramycin). 
'!he estimated effect size for this series of 11 studies was 
derived from the data shown in Table 7. '!he estimated effect size for 
this series was 0.007 with an associated standard deviation of 0.063 
and a 95% confidence interval of -0.116 to 0.131(Figure1). Since the 
aggregate effect sized estimate approxinates zero and the associated 
confidence interval encompasses zero (Table 6), it would appear from 
these results that there is no significant difference in the degree of 
nephrotoxicity between gentamicin and tobramycin. Technically, the 
interpretation of these results is that after treatment with either 
gentamicin or tobramycin, the sennn creatinine concentrations or 
creatinine clearances would not be different. Whether one chooses to 
interpret this to mean the degree of nephrotoxicity does not differ 
between the two drugs depends on whether sen.mi creatinine 
concentrations and creatinine clearances are accepted as representative 
Table 7 
Ccrrponents of Estimated Effect Size Calculation For 
Para:rretric Study Series 
Study 
Numbe.r 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Sum 
0.131 0.056 
-0.334 0.110 
1.666 0.122 
0.772 0.772 
0.420 0.206 
0.116 0.027 
-0.887 0.021 
0.294 0.016 
0.605 0.209 
-0.233 0.041 
-0.020 0.041 
2.345 17.692 
- 3.042 9.116 
13.606 8.166 
8.650 11.198 
1.989 4.849 
4.217 36.432 
-41.404 46.656 
18.713 63.566 
2.893 4.781 
- 5.659 24.335 
- 0.495 24.489 
1.813 251.551 
0.306 
1.016 
22.670 
6.681 
0.816 
0.488 
36.742 
5.509 
1. 751 
1.316 
0.010 
77.306 
~timated effect size. ~stimated effect size variance. 
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of renal function. 
HQ)llCXJeneity assumption. 'Ihe criterion for homogeneity among the 
11 studies was not met [Q (10, N = 11) = 77 .3, 12 < .05]. Inspection of 
Table 6 and Figure 1 suggested. that Study 3 (Gocdwin, 1979) and Study 7 
(Fong, Fenton, & Bird, 1981) may have contribute:i most to the 
heterogeneity among the studies. When these two studies were e:xclude:i 
from the analysis, the rema.ining nine studies met the criteria for 
homogeneity [Q (8, N = 9) = 13.4, 12 > .05]. 
'Ihe range of the estimate:i effect sizes among the nine 
homogeneous studies was from -0.334 to o. 772. 'Ihree of the estimate:i 
effect sizes we.re negative and six we.re positive values. 'Ihe estimate:i 
effect size standard deviations range:i from 0.125 to 0.457. 'Ihe 
widest 95% confidence interval was 1.81 and the narrowest 0.49. 'Ihe 
estimate:i effect size for the series of nine homogeneous studies was 
0.15 with an asscx::iate:i standard deviation of 0.005 and a 95% 
confidence interval of 0.01 to 0.29. 
'Ihe interpretation of comparative nephrotoxicity changes when the 
effect size estimate of only the nine homogeneous studies are 
considere:i belaw. Assl.Ilning a nonnal distribution, the average serum 
creatinine concentration or creatinine clearance in patients treate:i 
with gentamicin will exceed those of approximately 55% (standard nonnal 
deviate of 0.15) of the patients treate:i with tobramycin. Considering 
the 95% confidence interval, the average serum creat.inine 
concentration or creat.inine clearance in patients treate:i with 
gentamicin could exceed those of as many as approximately 61% (standard 
nonnal deviate of 0.29) or as few as 50% (standard deviate of 0.01) of 
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the patients treated with tobramycin. Again, the degree to which this 
represents a difference in the camparative nephrotoxicity of gentamicin 
arrl tobramycin will be depe:rxient on the degree to which these variables 
are acc::epte:i as representative of renal function. If these variables 
are accepted as representative, the clinical significance of the 
difference in camparative nephrotoxicity will be detennine:i by 
counter-balancing the excess risk of nephrotoxicity with the economic 
advantages associated with gentamicin use. 
Sensitivity analyses. Sensitivity analyses were conducted to 
dete.nnine whether any relationships existed between estimated effect 
sizes for irrl.ividual studies arrl certain study characteristics. The 
sensitivity analyses were restricted to the nine clinical trials that 
were hOinOg"eneous. 
With the ex~ion of one study, the sanple populations involve:i 
mostly adult patients (Table 2) • In Study 4 ( Itsarayoungyuen et al. , 
1982), the sample population include:i only neonates. The mean age was 
1. 5 days. By excluding this patient population, the estimate:i effect 
size for the remaining series of eight studies was 0.113 with an 
associated standard deviation of 0.073 arrl 95% confidence interval of 
-o. 031 to o. 257. The assumption of hOinOg"eneity remaine:i after 
exclusion of Study 4 (Q (7, N = 8) = 8.84 p > .05). 'Ihus, by 
including only clinical trials involving adult patients, the estimated 
effect size for the series of hOinOg"eneous studies involving mostly 
adult patients does not change appreciably from when the study 
involving neonates is included. 
The basis for the effect size estimate in all but one of the 
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studies was serum creat:i.nine concentrations. In Study 8 (Schentag et 
al. , 1981) , the basis for the effect size estimate was creatinine 
clearance. By excluding this study from the analysis, the estimated 
effect size for the remaining eight studies was 0.082 with an 
associated standard deviation of 0.087 and 95% confidence interval of 
-o. 088 to O. 252. Excluding Study 8 also reduced hetera;renei ty among 
the remaining eight studies [Q ( 7, N = 8) = 11. 4 9, p > . 05] • 'Ihus, by 
excluding Study 8 so that only homogeneous clinical trials employing 
serum creatinine concentrations as the endpoint are included in the 
analysis, the change in the aggregate estimated effect size is not of 
clinical significance. 
As shown in Table 2, for the studies reporting patient ages, the 
mean ages were always very similar within each study; hovvever, the mean 
ages differed between studies. 'Iherefore, mean age for both treatlnent 
groups were pooled within each study and regressed on estimated effect 
size. Age ao:::ounted for about 32% of the variability in estimated 
effect size; hovvever, this relationship did not reach statistical 
significance [x;-2 (6, N = 7) = .318, p = .085]. Of note was the 
direction of the relationship (regression coefficient of -1.012). As 
age increased, estimated effect size decreased. 'Ihis ma.y have been due 
to the inclusion of Study 4 (Itsarayoungyuen et al., 1982) which 
included only neonates and was associated with a relatively high effect 
size estimate. When this study was taken out of the analysis, the 
variability in estimated effect size associated with age decreased to 
approximately 9%; however, this relationship also did not reach 
statistical significance cr-2 (5, N = 6) = o.089, p = .264). 'Iherefore, 
it does not appear that any differences in nephrotoxicity associated. 
with gentamicin and tobramycin are linearly related. to pa.tient age 
(Table 8). 
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In the studies reporting the duration of gentamicin and 
tobramycin use, the durations of use were similar for both treatment 
groups for nearly all of the studies (Table 2) . Therefore, the 
durations of gentamicin and tobramycin use were pooled within studies 
and regressed on effect size estimates to determine 'Whether duration of 
use affected effect size estimates (Table 8) • OJ.ration of 
aminog1ycoside use accounted. for approximately 21% of the variability 
in estimated. effect size; h01Never, this relationship did not reach 
statistical significance [i;2 (7, N = 8) = .209, 12 = .121]. Thus, it 
does not appear that any differences in nephrotoxicity associated with 
gentamicin and tobramycin are linearly related. to the duration of use. 
Differences in initial renal function between treatment groups, 
as :measured by initial serum creatinine concentrations or creatinine 
clearances, existed. arocmg some of the clinical trials (Table 2); 
h01Never, not all were clinically significant. The differences between 
initial serum creatinine concentrations or creatinine clearances 
between treatment groups were regressed on effect size estimates (Table 
8). The differences in initial serum creatinine concentrations and 
creatinine clearances accounted. for approximately 16% of the 
variability in estimated. effect size; however, this relationship did 
not reach statistical significance ri;2 (7, N = 8) = .156, 12 = .159]. 
Variation existed. ainOng- the studies in the differences between 
the treatment groups in the incremental chang-es during therapy in serum 
Table 8 
Sensitivity Analysis - Linear Regre.ssian Analyses 
Variable C.oef ficient Ad.justed R2 D.F. a 
Age(l)c 
-1.012 .318 6 .09 
Age(2)d 
-0.045 .089 5 .26 
Duratione 
-0.061 .209 7 .12 
Initial CRf 0.007 .156 7 .16 
Increase CRg 
-0.002 .ooo 7 .88 
Randanh 0.105 .ooo 7 • 71 
Blindi 0.457 .299 7 .07 
'il.F. =degrees of free:'ian. hp =two-tailed probability of 
CXJefficient not ~ zero. cAge(l) =pooled ages for all 
harogeneous studies. ""Age(2) =pooled ages for all hqrogeneous 
studies excluding the study with neonates (Study 9) ~led 
duration of gentamicin and tobramycin use (days). foifference 
in initial serum creatinine concentration or creat.i.n.ine 
clearance between gentamicin arrl tobramycin groups. gDifference 
in incrE!l'elltal increase in serum creatinine concentration or 
~reatinine clearance between gentamicin arrl tobramycin gp:>UpS • 
.. Whether patients were ra.n:lanized to treatment groups. ~ether 
study was blinded. 
71 
creatinine concentrations or creatinine clearances (Tables 2 and 5). 
'lbe difference in incremental change between thetreatment groups were 
re;Jressed on the effect size estllna.tes (Table 8). 'lbe incremental 
change in serum creatinine concentration or creatinine clearance did 
not account for any variability in the estima.ted effect size 
c.r2 =.000): therefore, it does not appear that any differences in the 
incremental changes in measurements of renal function between 
gentarnicin and tobramycin are associated with a difference in 
nephrotoxicity. 
Only three studies were blinded (Study 9 (Feig et al., 1982), 
Study 6 (Smith et al., 1980), and Study 4 (Itsarayoungyuen et al., 
1982)] (Table 6). Blinding status did not appreciably affect effect 
size estima.tes and did not reach statistical significance 
[.r2 (7, N = 8) = .105, p = .71]. 
'1bree studies did not randomize patients to either treatment 
group (Study 2 (Kahlmeter et al., 1978), Study 5 (IX>nta & I.embke, 
1985), and Study 8 (Schentag et al., 1981)] (Table 8). Randomization 
status accounted for approxima.tely 30% of the variability in effect 
size estima.tes; however, this relationship did not reach statistical 
significance [_r2 (7, N = 9) = .299, p = .07). Of note was the 
direction of the relationship (regression coefficient of 0.105) 
suggest:i.rq that higher effect size estllna.tes (i.e. , differences in the 
degree of nephrotoxicity between gentarnicin and tobramycin) may be 
expected more often in randomized studies. 
Nonparametric Analyses 
Effect size estllna.tion. 'Ihe nonparametric estllna.tions of effect 
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size were based on the differences in the proportions of studies in 
which the nephrotoxicity incidence between the gentamicin groups and 
tobramycin groups reached statistical significance. 'Ihe proportion of 
studies in which the difference in the incidence of nephrotoxicity 
between gentamicin and tobramycin reached statistical significance by 
the Relative Deviate Test was 0.231 (3/13) with an associated 95% 
confidence interval of 0.002 to 0.437. 'Ihe estimated effect size based 
on this proportion was 0.117 with an associated 95% confidence interval 
of o to 0.226 (Table 9). 
Sensitivity Analysis. When the seven studies that could only be 
used in the nonparametric analyses were considered (Studies 12-18) , the 
proportion in which the difference in nephrotoxicity incidence between 
gentamicin and tobramycin reached statistical significance was O .14 
(1/7) with an associated 95% confidence interval of -0.116 to 0.402. 
The estimated effect size based on this proportion was 0.080 with an 
associated 95% confidence interval of -0.60 to 0.200. 
In the nonparametric analysis that included the studies that were 
also in the parametric analysis, one of the studies included [Study 7 
(Fong et al., 1981) J was one that was excluded in the homogeneous 
parametric analysis. When this study was eliminated from the 
nonparametric analysis, the proportion of studies in which the 
difference in nephrotoxicity incidence between gentamicin and 
tobramycin reached statistical significance was 0.25 (3/12) with an 
associated 95% confidence interval of 0.005 to 0.495. 'Ihe estimated 
effect size was 0.134 with an associated 95% confidence interval of o 
to 0.232. 
Table 9 
Estimated Effect Sizes for lbnpara:rootric Analyses 
Study 
Group a 
1 
2 
3 
Proportion of 
Dif f. Signi~ 
3/13 (23%) 
3/12 (25%) 
1/7 (14%) 
Clgtuiy groupin;Js: 
95% Confidence 
Interval of 
Proportion 
-0.008 - 0.437 
-0.001 - 0.469 
-0.116 - 0.402 
Estimated 
Effect. Size 
0.117 
0.134 
0.080 
1 =All stu:iies used in nonpara:rootric analysis (Studies 6-18). 
95% Confidence 
Interval of 
Effect Size 
0.000 - 0.226 
o.ooo - 0.232 
-0.060 - 0.200 
2 =Studies used in nonpara:rootric and harogeneous para:rootric analyses (Stu:iies 6, 8-18). 
3 = Stu:iies only used in nonpara:rootric analysis (Stu:iies·12-l8). 
~ of stuiies in which differences in proi;x>rtions nei;hrotaxic significant/total 
m.:mDer of studies. 
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'lhe nonparametric estimations of effect size were remarkably 
similar to those resulting from the parametric analysis. If one 
accepts the arbitrary definitions of nephrotoxicity in the studies used 
in the nonparametric analyses and serum creatinine concentrations or 
creatinine clearance as markersof nephrotoxicity, the interpretations 
of the nonparametric analysis results would parallel those of the 
parametric analysis. Using the same assunptions, it could be suggested. 
that the modified vote-counting method of Hedges and Cl.kin ( 1985) may 
be a reliable alteniative 'When the empirical research substrate 
provides only limited. infonnation (Table 10 and Figure 2). 
Summary 
Eighteen clinical studies related. to the corrparative 
nephrotoxicity of gentamicin and tobramycin met the criteria for this 
meta-analysis. Analysis by two different methods indicated. that if 
there is a difference in nephrotoxicity between the two drugs, it is 
not of a great magnitude. In addition, none of the selected. covariates 
affected. the difference in nephrotoxicity between gentamicin and 
tobramycin to an extent that reached statistical significance. 
Secondarily, the m::rlified vote-counting method produced very 
similar results as the parametric analysis (Table 10 and Figure 2). 
Thus, despite that conventional vote-counting methods are often 
dismissed as not being useful, the modified vote-counting method of 
Hedges and cl.kin (1985, chap. 4) may indeed have a role in situations 
'Where the ernpirical research under investigation does not provide 
enough infonna.tion to apply the more parametric procedures. 
Table 10 
Surrmary of Estimated Effect Sizes 
a Study Grrup 
1 
2 
3 
4 
5 
6 
7 
~ttrly groupin3'5: 
Mean Est:.ilrated 
Effect Size 
Parametric Analyses 
0.007 
0.150 
0.113 
0.082 
Nonpararretric Analyses 
0.117 
0.134 
0.080 
95% Confidence 
Interval 
-0.116 - 0.131 
0.010 - 0.290 
-0.031 - 0.257 
-0.088 - 0.252 
o.ooo - 0.226 
0.000 - 0.232 
-0.060 - 0.200 
1 =All stu::lies in parametric analysis (Stu::lies 1-11). 
2 = Harogeneous studies in parametric analysis (Study 
grouping 1 minus Study 3 and Study 7). 
3 =Study grouping 2 minus Study 4 (neonates). 
4 = Stt.rly grouping 2 minus Study 8 (creatinine clearance). 
5 =All studies in nonparametric analysis (Studies 6-18). 
6 = Stu:lies in nonpararretric an::l harogeneous pararretric 
analyses (Studies 6, 8-18). 
7 = Stu:iies only in nanpa.rarretric analysis (Studies 12-18). 
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Figure 2. Effect Size Estimates and 953 Confidence Jntervals 
For Parametric and Nonparametric Analyses. 
Nonparmetric 
Analyses 
Parametric 
Analyses 
Study 
Group* 
7 
6 
5 
4 
3 
2 
-0.2 -0. 1 0 0. 1 0.2 0.3 
Effect Size 
* As listed in Table l 0. 
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SUMMARY 
Aminoglycoside antibiotics are brp::>rtant agents in the 
treatment of serious to life-threatening bacterial infections. 
However, the use of these antibiotics is hanpere:l by an association 
with nephrotoxicity. Research efforts have been undertaken to 
determine whether any of the aminoglycoside antibiotics is less 
nephrotoxic than the others. Corrparisons of two aminoglycoside 
antibiotics in particular, gentamicin and tobramycin, have prcx:luced. 
equivocal results. Some data have suggeste:l that gentamicin is 
associate:l with nephrotoxicity to a greater degree than tobramycin 
while other data have suggeste:l no difference. Publishe:l reviews of 
the empirical gentamicin and tobramycin comparisons have been as 
equivocal with re;Jard to their ccnuparative nephrotoxicity as the 
empirical research they covere:l. Hc:Mever, none of the publishe:l 
reviews applie:l systematic meta-analytical techniques. 
In the investigation rep::>rted here, meta-analytical techniques 
were use:l to assess the empirical research conparing the nephrotoxicity 
of gentamicin and tobramycin in humans. Specifically, effect sizes 
were est.imate:l using the parametric approach of standa:rdize:l mean 
differences. In addition, a mcx:lifie:l vote-counting prcx::e::lure was use:l 
in those situations where there was insufficient info:nnation for 
parametric analysis. When all studies in the parametric analysis were 
include:l, there appeared. to be no difference in the degree of 
nephrotoxicity between gentamicin and tobramycin; hc:Mever, when only 
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homogeneous studies were included, it appeared that gentarnicin may 
Weed be associated with nephrotoxicity to a slightly greater degree. 
Interestingly, effect size estimates derived using the m::xlified 
vote-counting method produced similar results and. inte:rpretations. 
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